NACC Research Productivity - last update 3/14/2014

External Researchers Utilizing NACC Data: (TOTAL of 253)

2014 1. Anor CJ, Hu B, Multani N, Tartaglia MC. Examining the Association between Neuropsychiatric Symptoms, Hypertension, Hypercholesterolemia, and Diabetes in Alzheimer’s disease. AAIC 2014, submitted 2014. (Abstract)
  2. Benson G, de Felipe J, Xiaodong, Sano M. Performance of Spanish-speaking community-dwelling elders in the United States on the Uniform Data Set. Alzheimers and Dementia, in press 2014, PMC in process.
  3. Chen B, Qin J. Test the reliability of doubly robust estimation with missing response data. Biometrics, in press 2014, NIHMS560472.
  4. Cohen ML, Kim C, Haldiman T, ElHag M, Mehndiratta P, Pichet T, Lissemore F, Cohen Y, Chen W, Blevins J, Surewicz K, Surewicz W, Sajatovic M, Tatsuoka C, Zhang S, Lerner A, Safar JG. Distinct Structures of ?-Amyloid in Rapidly Progressive Alzheimer Disease. Ann Neurol, submitted 2014.
  5. Galkina E. Linked visual analysis of structured datasets and document collections. Visualization and Data Analysis 2014 Proceedings of SPIE, accepted 2014. (Abstract)
  6. Gaugler JE, Hovater M, Roth DL, Johnston JA, Kane RL, Sarsour K. Depressive, functional status, and neuropsychiatric symptom trajectories before an Alzheimer's disease diagnosis. Aging Mental Health, 18:110-116, 2014, PMC3855584.
  7. Gavett BE, Vudy V, Jeffrey M, John SE, Gurnani A, Adams J. The ? latent dementia phenotype in the NACC UDS: Cross-validation and extension. Alzheimers and Dementia, submitted 2014.
  8. Gifford KA, Liu D, Han X, Jefferson AL. Mutual cognitive complaint is related to neuropathological evidence of Alzheimer’s disease in mild cognitive impairment. AAIC 2014, submitted 2014. (Abstract)
  9. Grill JD, Monsell S. Choosing Alzheimer's disease prevention clinical trial populations. Neurobiol Aging, 35:466-471, 2014, PMC3864603.
  10. Gross AL, Mukherjee S, Sherva R, Newhouse S, Waterston LB, Jones RN, Green RC, Crane PK, ADNI Collaborators, GENAROAD Collaborators. Calibrating Longitudinal Cognitive Performance Across Diverse Neuropsychological Batteries and Datasets. AAIC 2014, submitted 2014. (Abstract)
  11. Herberger V, Hodges EK, Giordani B, Zhu J, Dodge HH. Type 2 Diabetes Mellitus: Longitudinal Impact on Cognition in Persons with Normal Cognition, MCI, and Dementia. AAIC 2014, submitted 2014. (Abstract)
  12. Hsiao JJ, Lu PH, Grill JD, Teng E. Longitudinal Declines in Instrumental Activities of Daily Living in Stable and Progressive Mild Cognitive Impairment. Dement Geriatr Cogn Disord, submitted 2014.
  13. Jefferson A. Hemodynamic factors underlying the pathogenesis and clinical expression. INS 2014, submitted 2014. (Abstract)
  14. Leger GC, Banks SJ. Neuropsychiatric Symptom Profile Differs Based on Pathology in Patients with Clinically Diagnosed Behavioral Variant Frontotemporal Dementia.. Dement Geriatr Cogn Disord, 37:104-112, 2014, PMC Journal - In Process.
  15. Li B, Chow TWS, Huang D. A novel feature selection method and its application. J Intelligent Information Systems, in press 2014, NIHMS558600.
  16. Liu D, Zhou XH. Estimation of ROC curve with multiple types of missing gold standard. ICSA 2013 Symposium Book, submitted 2014.
  17. Maddox RA, Blase JL, Mercaldo ND, Gambetti P, Harvey AR, Schonberger LB, Kukull WA, Belay ED. Clinically Unsuspected Prion Disease among Patients with Dementia Diagnoses. Neuroepidemiology, submitted 2014.
  18. Millikin C. Factors Associated with Development and Stability of Delusions in Probable Alzheimer’s Disease. Am Academy Geriatric Psych 2014, accepted 2014. (Abstract)
  19. Moga DC, Abner E, Jicha G. URINARY INCONTINENCE TREATMENT IN OLDER WOMEN ENROLLED IN THE NATIONAL ALZHEIMER’S COORDINATING CENTER COHORT. Path to Prevention of LUTS Workshop, Bethesda MD, submitted 2014. (Abstract)
  20. Nelson PT, Estus S, Abner EL, Parikh I, Malik M, Neltner JH, Ighodaro E, Schellenberg GA, Wang WX, Wilfred BR, Kukull WA, Nandakumar K, Farman ML, Kofler JK, Poon WW, Corrada M, Kawas CH, Jicha GA, Hubbard RA, Bennett DA, Schneider JA, Sonnen JA, Crane PK, Wang LS, Cantwell L, Valladares O, Van Eldik L, Larson EB, Horbinski C, Green RC, Gearing M, Kramer PL, Woltjer RL, Wang X, Kamboh IM, Montine TJ, Partch AB, Oliver K, Monsell SE, ADGC C, Fardo DW. Drug target ABCC9 is linked to a prevalent human disease: hippocampal sclerosis of aging. Acta Neuropathol, submitted 2014.
  21. Neltner JH, Abner EL, Baker S, Schmitt FA, Kryscio RJ, Jicha GA, Smith CD, Hammack E, Kukull WA, Brenowitz WD, Van Eldik LJ, Nelson PT. Arteriolosclerosis that affects multiple brain regions is linked to hippocampal sclerosis of ageing. Brain, 137:255-267, 2014, PMC3891448.
  22. Qiu WQ, Mwamburi M, Besser LM, Zhu H, Li H, Wallack M, Phillips L, Qiao L, Budson AE, Stern R, Kowall N. Angiotensin Converting Enzyme Inhibitors and the Reduced Risk of Alzheimer’s disease in the Absence of Apoliprotein E4 allele. J Alzheimers Dis, 22:177-185, 2014, PMC3873370.
  23. Ringman JM, Sachs MC, Zhou Y, Monsell SE, Saver JL, Vinters HV. Clinical predictors of severe cerebral amyloid angiopathy and influence of APOE genotype in persons with pathologically-verified Alzheimer’s disease. JAMA Neurology, in press 2014, NIHMS573878.
  24. Ronquillo JG, Baer MR, Lester WT. A big data approach to identifying and analyzing sex-specific patterns and differences in dementia and Alzheimer’s disease. JAMA Neurology, submitted 2014.
  25. Sadak TI, Katon J, Beck C, Cochrane BB, Borson S. Key neuropsychiatric symptoms in common dementias: prevalence and implications for caregivers, clinicians, and health systems. Res Gerongol Nurs, 7:44-52, 2014, PMC3909707.
  26. Sayegh P. The Role of Neuropsychological Language Tests in Clinician-rated Dementia Severity across Hispanics and Non-Hispanic Whites. International Neuropsychological Society 42nd Annual Meeting, Seattle, WA,, accepted 2014. (Abstract)
  27. Serrano-Pozo A, Qian J, Monsell S, Blacker D, Gomez-Isla MT, Betensky R, Growdon J, Frosch M, Sperling R, Hyman B. Mild to moderate Alzheimer dementia with insufficient neuropathological changes. Ann Neurol, in press 2014, NIHMS573418.
  28. Sherva R, Tripodis Y, Bennett DA, Chibnik LB, Crane PK, de Jager PL, Farrer LA, Saykin AJ, Shulman JM, Naj A, Green RC, ADGC Collaborators. Genome-wide association study of the rate of cognitive decline in Alzheimer's disease. Alzheimers and Dementia, 10:45-52, 2014, PMC3760995.
  29. Skinner J, Liu D, Xu M, Gifford K, Jefferson A. Stroke Risk Profile as a Predictor of Cognition in Minority Elders. Int Neuropsychological Society Annual Meeting, submitted 2014. (Abstract)
  30. Skinner JS, Liu D, Han X, Jefferson AL. Biracial differences in the distribution of cerebrovascular and Alzheimer’s disease neuropathology. AAIC 2014, submitted 2014. (Abstract)
  31. Snowden MB, Atkins DC, Steinman LE, Fitzpatrick AL, Bell JF, Bryant LL, Copeland C. Longitudinal Association of Dementia and Depression. JAMA, submitted 2014.
  32. Spiegel R. Validating the Placebo Group Simulation Approach (PGSA), an Alternative Study Design for Preventive Trials in Prodromal AD Patients. AAIC 2014, submitted 2014. (Abstract)
  33. Steed D. Teasing Apart Concurrent and Predictive Influences on Dementia and Neuropsychiatric Symptoms. International Neuropsychological Society Meeting, February 2014, accepted 2014. (Abstract)
  34. Tosto G. Latent Analysis of Extrapyramidal Signs In Alzheimer Disease Identifies Distinct Disease Expressions. AAIC 2014, submitted 2014. (Abstract)
  35. Woodruff B. Absence of a “widowhood effect” on incidence of dementia. AAIC 2014, submitted 2014. (Abstract)
  36. Woodruff B. Paradoxical impact of widowhood on incidence of dementia in subjects with Mild Cognitive Impairment. AAIC 2014, submitted 2014. (Abstract)
  37. Woon FL. Cognitive Predictors of Reversion to Normal Cognition from Mild Cognitive Impairment. Am Academy Clin N'psych 2014, submitted 2014. (Abstract)
  38. Woon FL. Medication use as a Predictor of Reversion from Mild Cognitive Impairment. Am Academy Clin N'psych 2014, submitted 2014. (Abstract)
2013 39. Altmann A, Tian L, Henderson VW, Greicius MD, ADNIInvestigators, NACC. Gender Modulates the Effect of APOE ?4 on Cognitive Decline. New England J Med, submitted 2013.
  40. Ascher-Svanum H, Gaugler J, Roth D, Fafowora T, Siderowf A, Beach T. Characteristics of Patients Misdiagnosed with Alzheimer’s Disease and Their Medication Use: An Analysis of the NACC-UDS Database. Alzheimers and Dementia, 9:P734, 2013. (Abstract)
  41. Ayutyanont N, Langbaum JBS, Hendrix SB, Fleisher AS, Caselli R, Monsell SE, Chen K, Kukull WA, Bennett D, Tariot PN, Reiman EM. Validation of the Alzheimer’s Prevention Initiative Composite Cognitive Test Score. Alzheimers and Dementia, 9:P320, 2013. (Abstract)
  42. Barnes J, Dickerson B, Frost C, Jiskoot LC, Wolk D, van der Flier WM. First symptoms in Alzheimer’s disease are age dependent: evidence from the large NACC dataset. Neurology, submitted 2013.
  43. Benitez BA, Jin SC, Harold D, Sims R, Graham R, Harari O, Bertelsen S, Bhangale T, Ortmann W, Behrens T, Guerreiro R, Sassi C, Mayeux R, Pericak-Vance MA, Farrer LA, Schellenberg GD, Fagan AM, Holtzman DM, Morris JC, ADGC Investigators, ADNI Investigators, GERAD Investigators, Singleton A, Kauwe J, Hardy J, Williams J, Goate AM, Cruchaga C. Missense variant in TREML2 reduces risk for AD independent of TREM2 R47H. Neurobiol Aging, in press 2013, NIHMS551919.
  44. Berres M, Kukull WA, Spiegel R. The Placebo Group Simulation Approach (PGSA): Its application to MCI data from the NACC database. Alzheimer Rsch & Therapy, submitted 2013.
  45. Bruns M, Bristow K, Monsell SE, Aakre J, Kukull W, Pankratz V, Knopman D, Graff-Radford N, Miller B, Laden F, Dickinson S, Mesulam M, Boeve B. Similar maximal educational attainment in people with dementia: Association with pathologically diagnosed frontotemporal lobar degeneration, Alzheimer's disease and Lewy body disease?. Alzheimers and Dementia, 9:P631, 2013. (Abstract)
  46. Bruns M, Pankratz VS, Wicklund M, Kukull W, Knopman D, Graff-Radford N, Miller B, Laden F, Mesulam MM, Boeve B. Educational Attainment in Patients with Frontotemporal Dementia and Primary Progressive Aphasia Compared to Other Dementia Syndromes. Neurology, 80:P03.089, 2013. (Abstract)
  47. Burnham R, Xiong C, McIntosh L. DYNAMIC AND INTERACTIVE VISUALIZATION: Interpreting NACC Uniform Data while Encompassing Missing Assessments. HEALTHINF 2014, 7th international conference on health informatics, submitted 2013.
  48. Chen B, Qin J. Use empirical likelihood to calibrate auxiliary information in isotonic regression models. Stat Med, in press 2013, NIHMS545137.
  49. Chen W, Albert MA, Han DF, Lyketsos CG, Rosenberg PB. Neuropathological correlates of apathy in Alzheimer’s Disease. Int Psychogeriatr, submitted 2013.
  50. Cheng Y, Trzepacz PT, Chang C, Hake AM, Siemers ER. Seizure and associated factors in patients with different types of dementia. Pharmacoepidemiol Drug Saf, 22(S1):266, 2013. (Abstract)
  51. Cocroft S. Alzheimer’s Disease and African Americans. North Central Sociological Association's annual meeting, 2013. (Abstract)
  52. Cosentino S, Schupf N, Christensen K, Anderson S, Newman A, Mayeux R. Reduced Prevalence of Cognitive Impairment in Families With Exceptional Longevity. JAMA Neurology, 70:867-874, 2013, NIHMS508895.
  53. Cruchaga C, Kauwe JS, Harari O, Jin SC, Cai Y, Karch CM, Benitez BA, Jeng AT, Skorupa T, Carrell D, Bertelsen S, Bailey M, McKean D, Shulman JM, De Jager PL, Chibnik L, Bennett DA, Arnold SE, Harold D, Sims R, Gerrish A, Williams J, Van Deerlin VM, Lee VM, Shaw LM, Trojanowski JQ, Haines JL, Mayeux R, Pericak-Vance MA, Farrer LA, Schellenberg GD, Peskind ER, Galasko D, Fagan AM, Holtzman DM, Morris JC, ADGC Collaborators, Goate AM. GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer's disease. Neuron, 78:256-268, 2013, PMC3664945.
  54. Cummings JL, Ringman J, Vinters H. Neuropathologic Correlates of Trial Related Instruments for Alzheimer’s Disease. submitted 2013.
  55. Dams-O'Connor K, Spielman L, Hammond FM, Sayed N, Culver C, Diaz-Arrastia R. An exploration of clinical dementia phenotypes among individuals with and without traumatic brain injury. Neurorehabilitation, 32:199-209, 2013, PMC3767178.
  56. De Felipe J, Benson G, Luo X, Sewell M, Sano M. Performance of Spanish Speaking Community dwelling elders in the US on the Uniform Data Set (UDS). Alzheimers and Dementia, 9:P621-623, 2013. (Abstract)
  57. Deutsch M, Mendez M, Teng E. Medical risk factors for frontotemporal degeneration: Analysis of the NACC Uniform Dataset. AAN 2014, submitted 2013. (Abstract)
  58. Farrer, LA. SORL1 is genetically associated with late-onset Alzheimer's disease in Japanese, Koreans and Caucasians. PLoS ONE, submitted 2013.
  59. Fowler NR, Johnson KG, Lie J, Moore CG, Saba S, Lopez O, Barnato AE. Prevalence and incidence of cardiac implantable electronic devices among older adults with cognitive impairment. Circulation, submitted 2013.
  60. Fowler NR, Sarles CE, Li J, Barnato AE. Prevalence and incidence of cardiac devices in a national Alzheimer’s Disease Centers sample. J Am Geriatr Soc, 61:S106-107, 2013. (Abstract)
  61. Fowler NR. Decision quality and the use of cardiac rhythm regulating devices in adults with cognitive impairment. Alzheimers and Dementia, 9:P634, 2013. (Abstract)
  62. Galkina EI.. Feasibility of pattern discovery in modeling cognitive decline in Alzheimer’s disease using the Weave platform. VizBi, accepted 2013. (Abstract)
  63. Gaugler JE, Ascher-Svanum H, Roth DL, Fafowora T, Siderowf A, Beach TG. Characteristics of patients misdiagnosed with alzheimer's disease and their medication use: an analysis of the NACC-UDS database. BMC Geriatrics, 13:137, 2013, PMC3878261.
  64. Giraldo M, Lopera F, Siniard AL, Corneveaux JJ, Schrauwen I, Carvajal J, Munoz C, Ramirez-Restrepo M, Gaiteri C, Myers AJ, Caselli RJ, Kosik KS, Reiman EM, Huentelman MJ. Variants in triggering receptor expressed on myeloid cells 2 are associated with both behavioral variant frontotemporal lobar degeneration and Alzheimer's disease. Neurobiol Aging, 34:2077 e11-8, 2013, PMC3830921.
  65. Goldstein FC, Levey AI, Steenland NK. High blood pressure and cognitive decline in mild cognitive impairment. J Am Geriatr Soc, 61:67-73, 2013, PMC3699694.
  66. Grill JD, Monsell S. Choosing Alzheimer’s disease prevention trial populations. J Nutr Health Aging, 17:815-816, 2013. (Abstract)
  67. Gross A, Sherva R, Mukherjee S, Newhouse S, Waterston L, Zavitz K, Bennett D, Jones R, Crane P, Green R, ADNI, GENAROAD. Calibration of a new approach for estimating general cognitive performance for GWAS of cognitive decline in Alzheimer's disease. Alzheimers and Dementia, 9:P697-698, 2013. (Abstract)
  68. Gross AL, Sherva R, Mukherjee SR, Newhouse S, Kauwe J, Saykin AJ, Bennett DA, Chibnik LB, Kraft P, Crane PK, Green RC. Genome-Wide Association Study of Rate of Cognitive Decline in Six Cohorts with Patients with Alzheimer's Disease. 66th GSA Annual Scientific Meeting, New Orleans, LA, accepted 2013. (Abstract)
  69. Gross AL, Sherva R, Mukherjee SR, Newhouse S, Waterston LB, Mungas DM, Green RC, Jones RN, Crane PK. Novel Approach for Calibrating Longitudinal Cognitive Performance in Older Adults. 66th GSA Annual Scientific Meeting, New Orleans, LA, accepted 2013. (Abstract)
  70. Gu Y, Scarmeas N, Cosentino S, Brandt J, Albert M, Blacker D, Dubois B, Mayeux R, Stern Y. Body Mass Change in Alzheimer’s Disease. Alzheimers and Dementia, 9:P206-207, 2013. (Abstract)
  71. Gu Y, Scarmeas N, Cosentino S, Brandt J, Albert M, Blacker D, Dubois B, Mayeux R, Stern Y. Change in Body Mass Index Before and After Alzheimer's Disease Onset. Curr Alzheimer Res, in press 2013, NIHMS543760.
  72. Hart KR, Hanfelt JJ. Robust Latent Class Analysis for Longitudinal Data. Joint Statistical Meeting (JSM) Montreal, Canada, 2013. (Abstract)
  73. Hayden KM, Kuchibhatla M, Plassman BL, Germain CM, Romero HR, Welsh-Bohmer KA. The Use of Reliable Change Indices to Complement Norms in the Early Identification of Cognitive Decline. Alzheimers and Dementia, 9:P535-536, 2013. (Abstract)
  74. Holton P, Ryten M, Nalls M, Trabzuni D, Weale ME, Hernandez D, Crehan H, Gibbs JR, Mayeux R, Haines JL, Farrer LA, Pericak-Vance MA, Schellenberg GD, Ramirez-Restrepo M, Engel A, Myers AJ, Corneveaux JJ, Huentelman MJ, Dillman A, Cookson MR, Reiman EM, Singleton A, Hardy J, Guerreiro R, ADGC Consortium. Initial assessment of the pathogenic mechanisms of the recently identified Alzheimer risk Loci. Annals Human Genetics, 77:85-105, 2013, PMC3578142.
  75. Hsiao JJ, Lee GJ, Lu PH, Teng E. Longitudinal declines in instrumental activities of daily living in stable and progressive mild cognitive impairment. Neurology, 80:P07.154, 2013. (Abstract)
  76. Hutchinson KS. Risk factors for apathy in Alzheimer's disease. Doctoral Dissertation, Fielding Graduate University, submitted 2013.
  77. Jefferson AL, Hohman TJ, Liu D, Skinner JS, Lu Z, Sparling J, Gifford KA, Sumner EC. An Elevated Framingham Stroke Risk Profile is Related to Cognitive Decline Among Cognitively Normal Elders. Circulation, submitted 2013.
  78. Jicha G, Nelson P, Fardo D, Kryscio R, Schmitt F, Smith C, Neltner J, Van Eldik L, Kukull W, Abner E. Vascular neuropathology in dementia patients receiving antipsychotic therapy. Alzheimers and Dementia, 9:P303, 2013. (Abstract)
  79. Joshi A, Teng E, Tassniyom K, Mendez MF. Hippocampal and Mesial Temporal Sclerosis in Early-Onset Frontotemporal Lobar Degeneration Versus Alzheimer's Disease. Am J Alzheimers Dis Other Demen, in press 2013, NIHMS556164.
  80. Joshi A, Teng E, Tassniyom K, Shapira JS, Mendez MF. Hippocampal and medial temporal sclerosis in behavioral variant frontotemporal dementia. Neurology, 80:S44.007, 2013. (Abstract)
  81. Kalapatapu RK, Delucchi KL. APOE e4 genotype and cigarette smoking in adults with normal cognition and mild cognitive impairment: a retrospective baseline analysis of a national dataset. Am J Drug Alcohol Abuse, 39:219-226, 2013, PMC3710309.
  82. Kaur, B, Harvey, DJ, DeCarli, CS, Zhang, L, Sabbagh, MN and Olichney, JM. Extrapyramidal signs by dementia severity in Alzheimer disease and dementia with Lewy bodies. Alzheimer Dis Assoc Disord, 27:226-232, 2013, PMC3562426.
  83. Kremen S, Tassniyom K, Mendez M, Teng E. Extrapyramidal Signs in Primary Progressive Aphasia: Analyses of the NACC UDS Cohort. Neurology, 80:P06.071, 2013. (Abstract)
  84. Lane EM, Liu D, Lu Z, Niswender KD, Jefferson AL. The Differential Impact of Diabetes Medications on Cognition. Alzheimers and Dementia, 9:P206, 2013. (Abstract)
  85. Lane EM, Liu D, Xu M, Bell SP, Niswender KD, Jefferson AL. The Impact of Diabetes Medications on Alzheimer’s Disease and Vascular Neuropathology. Int'l Neuropsychological Society Meeting, submitted 2013. (Abstract)
  86. Liu W, Zhang B, Zhang Z, Zhou XH. Joint Modeling of Transitional Patterns of Alzheimer's Disease. PLoS ONE, 8:e75487, 2013, PMC3779177.
  87. Macklin EA, Blacker D, Hyman BT, Betensky RA. Improved Design of Prodromal Alzheimer's Disease Trials through Cohort Enrichment and Surrogate Endpoints. J Alzheimers Dis, 36:475-486, 2013, PMC3779898.
  88. Mayambala C. The Epidemiology of Alzheimers disease in Washington State. Am Public Health Assoc Conference, submitted 2013. (Abstract)
  89. McDavid A, Crane PK, Newton KM, Crosslin DR, McCormick W, Weston N, Ehrlich K, Hart E, Harrison R, Kukull WA, Rottscheit C, Peissig P, Stefanski E, McCarty CA, Zuvich RL, Ritchie MD, Haines JL, Denny JC, Schellenberg GD, de Andrade M, Kullo I, Li R, Mirel D, Crenshaw A, Bowen JD, Li G, Tsuang D, McCurry S, Teri L, Larson EB, Jarvik GP, Carlson CS. Enhancing the Power of Genetic Association Studies through the Use of Silver Standard Cases Derived from Electronic Medical Records. PLoS ONE, 8:e63481, 2013, PMC3677889.
  90. Mendez MF, Joshi A, Tassniyom K, Teng E, Shapira JS. Clinicopathological Differences Among Patients with Clinical Behavioral Variant Frontotemporal Dementia. Neurology, 80:561-568, 2013, PMC3589292.
  91. Mez J, Cosentino S, Brickman AM, Huey ED, Manly JJ, Mayeux R. Dysexecutive versus amnestic Alzheimer disease subgroups: analysis of demographic, genetic, and vascular factors. Alzheimer Dis Assoc Disord, 27:218-225, 2013, PMC3748394.
  92. Mez J, Cosentino S, Brickman AM, Huey ED, Manly JJ, Mayeux R. Faster cognitive and functional decline in Dysexecutive versus amnestic Alzheimer's subgroups: a longitudinal analysis of the National Alzheimer's Coordinating Center (NACC) database. PLoS ONE, 8:e65246, 2013, PMC3670903.
  93. Mez J, Cosentino S, Brickman AM, Huey ED, Mayeux R. Different demographic, genetic, and longitudinal traits in language versus memory Alzheimer's disease subgroups. J Alzheimers Dis, 37:137-146, 2013, PMC3877683.
  94. Miyashita A, Koike A, Jun G, Wang LS, Takahashi S, Matsubara E, Kawarabayashi T, Shoji M, Tomita N, Arai H, Asada T, Harigaya Y, Ikeda M, Amari M, Hanyu H, Higuchi S, Ikeuchi T, Nishizawa M, Suga M, Kawase Y, Akatsu H, Kosaka K, Yamamoto T, Imagawa M, Hamaguchi T, Yamada M, Moriaha T, Takeda M, Takao T, Nakata K, Fujisawa Y, Sasaki K, Watanabe K, Nakashima K, Urakami K, Ooya T, Takahashi M, Yuzuriha T, Serikawa K, Yoshimoto S, Nakagawa R, Kim JW, Ki CS, Won HH, Na DL, Seo SW, Mook-Jung I, St George-Hyslop P, Mayeux R, Haines JL, Pericak-Vance MA, Yoshida M, Nishida N, Tokunaga K, Yamamoto K, Tsuji S, Kanazawa I, Ihara Y, Schellenberg GD, Farrer LA, Kuwano R. SORL1 is genetically associated with late-onset Alzheimer's disease in Japanese, Koreans and Caucasians. PLoS ONE, 8:e58618, 2013, PMC3614978.
  95. Obermann KR, Morris JC, Roe CM. Exploration of 100 commonly used drugs and supplements on cognition in older adults. Alzheimers and Dementia, 9:724-732, 2013, PMC3823812.
  96. Pillai JA, Bonner-Jackson A, Walker E, Mourany L, Cummings JL. Higher working memory scores predict slower functional decline in autopsy confirmed Alzheimer’s disease. Neurology, submitted 2013.
  97. Piper BJ, Yasen AL, Taylor AE, Ruiz JR, Gaynor JW, Dayger CA, Gonzalez-Gross M, Kwon OD, Nilsson LG, Day IN, Raber J, Miller JK. Non-replication of an association of Apolipoprotein E2 with sinistrality. Laterality, 18:251-261, 2013, PMC3770935.
  98. Reitz C, Jun G, Naj A, Rajbhandary R, Vardarajan BN, Wang LS, Valladares O, Lin CF, Larson EB, Graff-Radford NR, Evans D, De Jager PL, Crane PK, Buxbaum JD, Murrell JR, Raj T, Ertekin-Taner N, Logue M, Baldwin CT, Green RC, Barnes LL, Cantwell LB, Fallin MD, Go RC, Griffith P, Obisesan TO, Manly JJ, Lunetta KL, Kamboh MI, Lopez OL, Bennett DA, Hendrie H, Hall KS, Goate AM, Byrd GS, Kukull WA, Foroud TM, Haines JL, Farrer LA, Pericak-Vance MA, Schellenberg GD, Mayeux R, ADGC Collaborators. Variants in the ATP-binding cassette transporter (ABCA7), apolipoprotein E 4,and the risk of late-onset Alzheimer disease in African Americans. JAMA, 309:1483-1492, 2013, PMC3667653.
  99. Reitz C, Tosto G, Vardarajan B, Rogaeva E, Ghani M, Rogers RS, Conrad C, Haines JL, Pericak-Vance MA, Fallin MD, Foroud T, Farrer LA, Schellenberg GD, George-Hyslop PS, Mayeux R, ADGC Collaborators. Independent and epistatic effects of variants in VPS10-d receptors on Alzheimer disease risk and processing of the amyloid precursor protein (APP). Translational Psychiatry, 3:e256, 2013, PMC3669917.
  100. Ridge PG, Mukherjee S, Crane P, Kauwe JSK, ADGC Collaborators. Alzheimer’s Disease: Analyzing the Missing Heritability. PLoS ONE, 8:e79771, 2013, PMC3820606.
  101. Rosenberg PB, Han D, Leoutsakos JM, Rattinger GB, Stuart EA, Oh ES, Lyketsos CG. Psychotropic medication exposure and cognitive, functional, and neuropsychiatric outcomes in Alzheimer’s Disease (AD). Am J Psychiatry, submitted 2013.
  102. Rosenberg PB, Mielke MM, Appleby BS, Oh ES, Geda YE, Lyketsos CG. The Association of Neuropsychiatric Symptoms in MCI with Incident Dementia and Alzheimer's Disease. Am J Geriatr Psychiatry, 21:685-695, 2013, PMC3428504.
  103. Sayed N, Culver C, Dams-O'Connor K, Hammond F, Diaz-Arrastia R. Clinical phenotype of dementia after traumatic brain injury. J Neurotrauma, 30:1117-1122, 2013, PMC3705947.
  104. Sayegh P, Knight BG. Assessment and diagnosis of dementia in Hispanic and non-Hispanic white outpatients. Gerontologist, 53:760-769, 2013, PMC3771673.
  105. Sayegh P, Knight BG. Functional Assessment and Neuropsychiatric Inventory Questionnaires: Measurement Invariance Across Hispanics and Non-Hispanic Whites. Gerontologist, in press 2013, PMC Journal - In Process.
  106. Sayegh P. Neuropsychological Language Tests in Dementia Diagnosis in Hispanic and Non-Hispanic White Outpatients. J Int Neuropsychol Soc, submitted 2013.
  107. Serrano-Pozo A, Qian J, Monsell SE, Frosch MP, Betensky RA, Hyman BT. Examination of the clinicopathologic continuum of Alzheimer disease in the autopsy cohort of the National Alzheimer Coordinating Center. J Neuropathol Exp Neurol, 72:1182-1192, 2013, NIHMS556747.
  108. Sherva R, Gross AL, Mukherjee SR, Newhouse S, Kauwe J, Munsie L, Saykin AJ, Bennett DA, Chibnik LB, DeJager P, Kraft P, Crane PK, Green RC. GWAS of Rate of Cognitive Decline in Six AD Cohorts. 63rd Annual Meeting of The American Society of Human Genetics, Boston MA, 2013. (Abstract)
  109. Shim YS, Roe CM, Buckles VD, Morris JC. Clinicopathologic Study of Alzheimer's Disease: Alzheimer Mimics. J Alzheimers Dis, 35:799-811, 2013, PMC3725959.
  110. Soto-Campos G, Yev AP, Soto CA. A Markov Chain Model for the Dynamics of Cognitive Decline in an Elderly USA Population Using Data from the Health and Retirement Study. Int J Aging Society, in press 2013, PMC in process.
  111. Spackman DE, Kadiyala S, Neumann PJ, Veenstra DL, Sullivan SD. The Validity of Dependence as a Health Outcome Measure in Alzheimer's Disease. Am J Alzheimers Dis Other Demen, 28:245-252, 2013, PMC3690581.
  112. Spiegel R, Berres M, Kukull WA. The Placebo Group Simulation Approach (PGSA) for Long-term Clinical Trials in Prodromal AD Patients - Confirmatory Study in an NACC Data Set. Alzheimer Rsch & Therapy, revision 2013.
  113. Steenland K, Zhao L, Goldstein FC, Levey A. Statins and cognitive decline in older adults with normal cognition or mild cognitive impairment. J Am Geriatr Soc, 61:1449-1455, 2013, PMC3773248.
  114. Sullivan C, Rabins PV, Brandt J, Onyike CU. Cognitive and Behavioral Features of Neuropathology-defined Hippocampal Sclerosis Dementia. Neurology, submitted 2013.
  115. Tartaglia MC, Hu B, Mehta K, Neuhaus J, Yaffe K, Miller BL, Boxer A. Demographic and neuropsychiatric factors associated with off-label medication use in frontotemporal dementia and Alzheimer’s disease. Alzheimer Dis Assoc Disord, in press 2013, NIHMS519607.
  116. Teng YL. The Alzheimer's Disease Centers Uniform Data Set (UDS): Using various algorithms to predict dementia types with MMSE and CDR. submitted 2013. (Abstract)
  117. Thambisetty M, An Y, Tanaka T. Alzheimer's disease risk genes and the age-at-onset phenotype. Neurobiol Aging, 34:2696.e1-2696.e5, 2013, NIHMS490767.
  118. Toledo JB, Arnold SE, Brettschneider J, Lee EB, Xie SX, Grossman M, Monsell SM, Kukull WA, Trojanowski JQ. Importance of coincident neurodegenerative diseases. Alzheimers and Dementia, 9:P334, 2013. (Abstract)
  119. Toledo JB, Arnold SE, Raible K, Brettschneider J, Xie SX, Grossman M, Monsell SE, Kukull WA, Trojanowski JQ. Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer's Coordinating Centre. Brain, 136:2697-2706, 2013, PMC3858112.
  120. Trzepacz PT, Saykin A, Yu P, Bhamditipati P, Sun J, Dennehy EB, Willis B, Cummings JL. Subscale validation of the neuropsychiatric inventory questionnaire: comparison of Alzheimer's disease neuroimaging initiative and national Alzheimer's coordinating center cohorts. Am J Geriatr Psychiatry, 21:607-622, 2013, PMC3913908.
  121. Tsuang D, Leverenz JB, Lopez OL, Hamilton RL, Bennett DA, Schneider JA, Buchman AS, Larson EB, Crane PK, Kaye JA, Kramer P, Woltjer R, Trojanowski JQ, Weintraub D, Chen-Plotkin AS, Irwin DJ, Rick J, Schellenberg GD, Watson S, Kukull W, Nelson PT, Jicha GA, Neltner JH, Galasko D, Masliah E, Quinn JF, Chung KA, Yearout D, Mata IF, Wan JY, Edwards KL, Montine TJ, Zabetian CP. APOE ?4 Increases Risk for Dementia in Pure Synucleinopathies. JAMA Neurology, 70:223-228, 2013.
  122. Viswanathan A, Macklin EA, Betensky R, Hyman B, Smith EE, Blacker D. Vascular Risk Factors and Cognitive Decline in Older Adults: A Longitudinal Analysis of the National Alzheimer Coordinating Center (NACC) cohort. Alzheimer Dis Assoc Diord, submitted 2013.
  123. Wallack M, Zhu H, Mwamburi M, Phillips LE, Budson A, Kowall N, Stern R, Qiu WQ. Apolipoprotein E Allele, Angiotensin-Converting Enzyme and its inhibitors, in the Development of Alzheimer's Disease. Alzheimers and Dementia, 9:P616-617, 2013. (Abstract)
  124. Wangoria E, Wordoffa H. Alzheimer's Disease Stage Prediction using Machine Learning and Multi Agent System. Thesis, Blekinge Inst of Tech, School of Computing, 2013.
  125. Wyman-Chick K. Clinical Utility of the Clinical Dementia Rating Scale for Parkinson's Disease Dementia. A Dissertation Submitted to the Faculty of the School of Professional Psychology, Pacific Univeristy, Hillsboro, Oregon, 2013.
  126. Xie Y, Zimmerman DL. Antedependence models for nonstationary categorical longitudinal data with ignorable missingness: likelihood-based inference. Stat Med, 32:3274-3289, 2013, PMC3885186.
  127. Zhao MB, Chan RHM, Tang P, Chow TWS, Wong SWH. Trace Ratio Linear Discriminant Analysis for Medical Diagnosis: A Case Study of Dementia. IEEE Signal Processing Letters, 20:431-434, 2013, PMC3784002.
  128. Zhu JY, Vandermorris S, Craik FIM. Digit Symbol Substitution as a Marker of Asymptomatic AD. J Int Neuropsychol Soc, 19(S1):222, 2013. (Abstract)
2012 129. Allen M, Zou F, Chai HS, Younkin CS, Crook J, Pankratz VS, Carrasquillo MM, Rowley CN, Nair AA, Middha S, Maharjan S, Nguyen T, Ma L, Malphrus KG, Palusak R, Lincoln S, Bisceglio G, Georgescu C, Schultz D, Rakhshan F, Kolbert CP, Jen J, Haines JL, Mayeux R, Pericak-Vance MA, Farrer LA, Schellenberg GD, Petersen RC, Graff-Radford NR, Dickson DW, Younkin SG, Ertekin-Taner N.. Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology, 79:221-228, 2012, PMC3398432.
  130. Banks S, Leger G. Neuropsychiatric symptom profile differs based on pathology in patients with clinically diagnosed frontotemporal dementia. Dement Geriatr Cogn Disord, 34 (Suppl 1):213, 2012. (Abstract)
  131. Beach T, Monsell S, Phillips L, Kukull W. Accuracy of the Clinical Diagnosis of Alzheimer’s Disease at National Institute on Aging Alzheimer's Disease Centers, 2005-2010. J Neuropathol Exp Neurol, 71:266-273, 2012, PMC3331862.
  132. Bhatta R, Chou SY, Cantwell L, Schellenberg G, Wang LS. Alzheimer’s Disease and toxicity exposure: a gene-environment interactions analysis. American Society for Health Economics Conference Minneapolis, MN June, 2012. (Abstract)
  133. Coppola G, Chinnathambi S, Lee JJ, Dombroski BA, Baker MC, Soto-Ortolaza AI, Lee SE, Klein E, Huang AY, Sears R, Lane JR, Karydas AM, Kenet RO, Biernat J, Wang LS, Cotman CW, Decarli CS, Levey AI, Ringman JM, Mendez MF, Chui HC, Le Ber I, Brice A, Lupton MK, Preza E, Lovestone S, Powell J, Graff-Radford N, Petersen RC, Boeve BF, Lippa CF, Bigio EH, Mackenzie I, Finger E, Kertesz A, Caselli RJ, Gearing M, Juncos JL, Ghetti B, Spina S, Bordelon YM, Tourtellotte WW, Frosch MP, Vonsattel JP, Zarow C, Beach TG, Albin RL, Lieberman AP, Lee VM, Trojanowski JQ, Van Deerlin VM, Bird TD, Galasko DR, Masliah E, White CL, Troncoso JC, Hannequin D, Boxer AL, Geschwind MD, Kumar S, Mandelkow EM, Wszolek ZK, Uitti RJ, Dickson DW, Haines JL, Mayeux R, Pericak-Vance MA, Farrer LA, ADGC Collaborators, Ross OA, Rademakers R, Schellenberg GD, Miller BL, Mandelkow E, Geschwind DH. Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases. Hum Mol Genet, 21:3500-3512, 2012, PMC3392107.
  134. Gavett, BE. Dementia has a Categorical, not Dimensional, Latent Structure. Psychol Aging, 27:791-797, 2012, PMC3445289.
  135. Grill JD, Monsell S, Karlawish J. Are patients whose study partners are spouses more likely to be eligible for Alzheimer’s disease clinical trials?. Dement Geriatr Cogn Disord, 33:334-340, 2012, PMC3477789.
  136. Gustafson DR, Gill DP, Monsell SE. Evaluating sex differences and vascular morbidities in relation to global cognitive function in incident Alzheimer's disease. Alzheimers and Dementia, 8:P496, 2012. (Abstract)
  137. Hajjar I, Brown L, Mack W, Chui H. Impact of angiotensin receptor blockers on Alzheimer's disease neuropathology in a large brain autopsy series. Arch Neurol, 69:1632-1638, 2012, PMC3608189.
  138. Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, Mirra SS, Nelson PT, Schneider JA, Thal DR, Thies B, Trojanowski JQ, Vinters HV, Montine TJ. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers and Dementia, 8:13-Jan, 2012, PMC3266529.
  139. Jefferson, AL, Sparling, J, Gifford, K, Cantwell, N, Martin, B, Tripodis, Y. An elevated vascular health index is related to worse cognitive performance in individuals with mild cognitive impairment. Int'l Neuropsychological Society Meeting, 2012. (Abstract)
  140. Jun G, Vardarajan BN, Buros J, Yu CE, Hawk MV, Dombroski BA, Crane PK, Larson EB. Comprehensive search for Alzheimer disease susceptibility loci in the APOE region. Arch Neurol, 69:1270-1279, 2012, PMC3579659.
  141. Knopman D, Weintraub S, Pankratz VS. Augmented (8-item) Clinical Dementia Rating Scale is an effective instrument for longitudinal studies of bvFTD and PPA. Dement Geriatr Cogn Disord, 34 (Suppl 1):21-22, 2012. (Abstract)
  142. Lee GJ, Elashoff D, Di LJ, Teng E, Melchor S, Lu PH. Age-Associated Memory Impairment Increases Risk of Conversion to MCI and Dementia. Alzheimers and Dementia, 8:P544, 2012. (Abstract)
  143. Mendez M, Joshi A, Tassniyom K, Teng E. Clinicopathological differences among patients meeting clinical criteria for behavioral variant frontotemporal dementia. Dement Geriatr Cogn Disord, 34 (Suppl 1):260-261, 2012. (Abstract)
  144. Mez J, Consentino S, Brickman A, Huey E, Manley J, Mayeux R. Cognitive and functional decline in dysexecutive versus amnestic Alzheimer’s. Alzheimers and Dementia, 8:P635-P636, 2012. (Abstract)
  145. Mez J, Cosentino S, Brickman A, Huey E, Manly J, Mayeux R. Characterization of Dysexecutive Versus Amnestic Alzheimer's Disease Phenotypes in the National Alzheimer's Coordinating Center (NACC) Database. Neurology, 78(S), 2012. (Abstract)
  146. Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, Mirra SS, Nelson PT, Schneider JA, Thal DR, Trojanowski JQ, Vinters HV, Hyman BT. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol, 123:11-Jan, 2012, PMC3268003.
  147. Morris JC. Revised criteria for Mild Cognitive Impairment may compromise the diagnosis of Alzheimer Disease dementia. Arch Neurol, 69:700-708, 2012, PMC3423496.
  148. Nandipati, S, Luo, X, Schimming, C, Grossman, H and Sano, M. Cognition in Non-Demented Diabetic Older Adults. Curr Aging Science, 5:131-135, 2012, PMC3659164.
  149. Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ, Castellani RJ, Crain BJ, Davies P, Del Tredici K, Duyckaerts C, Frosch MP, Haroutunian V, Hof PR, Hulette CM, Hyman BT, Iwatsubo T, Jellinger KA, Jicha GA, Kovari E, Kukull WA, Leverenz JB, Love S, Mackenzie IR, Mann DM, Masliah E, McKee AC, Montine TJ, Morris JC, Schneider JA, Sonnen JA, Thal DR, Trojanowski JQ, Troncoso JC, Wisniewski T, Woltjer RL, Beach TG. Correlation of Alzheimer’s Disease Neuropathologic Changes with Cognitive Status: a Review of the Literature. J Neuropathol Exp Neurol, 71:362-381, 2012, PMC3560290.
  150. Olchanski N, Lin PJ, Cohen JT, Neumann PJ. Alzheimer’s disease progression rates: new estimates. American Neurological Association Annual Meeting in Boston, MA, Oct 8, 2012. (Abstract)
  151. Pirraglia E, Lobach I, De Santi S, Karantzoulis S, Glodzik L, de Leon MJ. A Comparison of Methods for Deriving Normative Scores for Evaluating Cognitive Impairment. Alzheimers and Dementia, 8:P541-P542, 2012. (Abstract)
  152. Pirraglia E, Murray J, De Santi S, Mosconi L, Glodzik L, de Leon MJ. Maternal History and Impaired Memory Predicts Future Decline to Dementia in Cognitively Normal Individuals. Alzheimers and Dementia, 8:P542, 2012. (Abstract)
  153. Sadak T, Katon J, Borson S. Defining Dementia Multimorbidity in a National Sample. J Am Geriatr Soc1, 60:S62, 2012. (Abstract)
  154. Sadak T, Katon J, Borson S. Multimorbidity in Alzheimer’s Disease and Related Dementias. Alzheimers and Dementia, 8:P490-P491, 2012. (Abstract)
  155. Sadak T, Kukull W, Borson S, Logsdon R, Cochrane B, Herting J. Multidimensional Complexity in the Dementias: Diagnosis, Stage, Comorbidity, and Neuropsychiatric Symptoms. Neurology, 78(S), 2012. (Abstract)
  156. Sayed N, Culver C, Hammond R, Diaz-Arrastia R. Clinical and Pathologic Phenotype of Dementia after Traumatic Brain Injury. National Neurotrauma Society, 2012. (Abstract)
  157. Sayegh P, Knight BG. Assessing the Cross-Cultural Measurement Properties of the Neuropsychiatric Inventory Questionnaire. Gerontological Society of America 65th Annual Scientific Meeting, San Diego, CA, 2012. (Abstract)
  158. Sayegh P, Knight BG. The Functional Assessment Questionnaire: Measurement Properties in Hispanics and Non-Hispanic Whites. Gerontological Society of America 65th Annual Scientific Meeting, San Diego, CA, 2012. (Abstract)
  159. Spackman, DE, Kadiyala, S, Neumann, PJ, Veenstra, DL and Sullivan, SD. Measuring Alzheimer disease progression with transition probabilities: Estimates from NACC-UDS. Curr Alzheimer Res, 9:1050-1058, 2012, PMC3690579.
  160. Spering CC, Hobson V, Lucas JA, Menon CV, Hall JR, O'Bryant SE. Diagnostic accuracy of the MMSE in detecting probable and possible Alzheimer's disease in ethnically diverse highly educated individuals: an analysis of the NACC database. J Gerontol, 67:890-896, 2012, PMC3403860.
  161. Spiegel R. Modeling the Course of AD: Contributions to Better Clinical Trials. J Nutr Health Aging, 811-812, 2012. (Abstract)
  162. Steenland K, Karnes C, Seals R, Carnevale C, Hermida A, Levey A. Late-life depression as a risk factor for mild cognitive impairment or Alzheimer's disease in 30 US Alzheimer's disease centers. J Alzheimers Dis, 31:265-275, 2012, PMC3729228.
  163. Sullivan C, Onyike C, Brandt J. The clinical features of neuropathology-confirmed Hippocampal Sclerosis Dementia. 41st mtg Intl Neuropsychological Society, 2012. (Abstract)
  164. Teng E, Tassniyom K, Lu PH. Reduced quality-of-life ratings in mild cognitive impairment: analyses of subject and informant responses. Am J Geriatr Psychiatry, 20:1016-1025, 2012, PMC3513348.
  165. Whitcomb DC, LaRusch J, Krasinskas AM, Klei L, Smith JP, Brand RE, Neoptolemos JP, Lerch MM, Tector M, Sandhu BS, Guda NM, Orlichenko L, Alkaade S, Amann ST, Anderson MA, Baillie J, Banks PA, Conwell D, Cote GA, Cotton PB, DiSario J, Farrer LA, Forsmark CE, Johnstone M, Gardner TB, Gelrud A, Greenhalf W, Haines JL, Hartman DJ, Hawes RA, Lawrence C, Lewis M, Mayerle J, Mayeux R, Melhem NM, Money ME, Muniraj T, Papachristou GI, Pericak-Vance MA, Romagnuolo J, Schellenberg GD, Sherman S, Simon P, Singh VP, Slivka A, Stolz D, Sutton R, Weiss FU, Wilcox CM, Zarnescu NO, Wisniewski SR, O'Connell MR, Kienholz ML, Roeder K, Barmada MM, Yadav D, Devlin B. Common genetic variants in the CLDN2 and PRSS1-PRSS2 loci alter risk for alcohol-related and sporadic pancreatitis. Nature Genetics, 44:1349-1354, 2012, PMC3510344.
  166. Wingo, TS, Lah, JL, Levey, AI, Cutler, DJ,. Autosomal Recessive Causes Likely in Early-Onset Alzheimer Disease. Arch Neurol, 69:59-64, 2012, PMC3332307.
  167. Zou F, Chai HS, Younkin CS, Crook J, Pankratz VS, Allen M, Carrasquillo MM, Rowley CN, Nair AA, Middha S, Maharjan S, Nguyen T, Ma L, Malphrus KG, Palusak R, Lincoln S, Bisceglio G, Georgescu C, Kouri N, Kolbert CP, Jen J, Haines JL, Mayeux R, Pericak-Vance MA, Farrer LA, Schellenberg GD, AD Genetics Consortium, Petersen RC, Graff-Radford NR, Dickson DW, Younkin SG, Ertekin-Taner N. Brain Expression Genome-Wide Association Study (eGWAS) Identifies Human Disease-Associated Variants. PLoS genetics, 8:e1002707, 2012, PMC3369937.
2011 168. Abner, EL, Kryscio, JR, Schmitt, FA, Frederick, A, Santacruz, KA, Jicha, GA, Y, L, Neltner, JM, Smith, CD, Charles, D, Van Eldik, LJ, Linda, J and Nelson, PT. "End-stage" neurofibrillary tangle pathology in preclinical Alzheimer's disease-fact or fiction. J Alzheimers Dis, 25:445-453, 2011, PMC3171001.
  169. Beach, T, Monsell, S, Phillips, L and Kukull, WA. Comparison of Clinical and Neuropathological Definitions of Alzheimer's Disease at National Institute on Aging Alzheimer's Disease Centers, 2005-2010. Alzheimer's and Dementia, 7:S525, 2011. (Abstract)
  170. Bliwise, DL, Mercaldo, ND, Avidan, AY, Boeve, BF, Greer, SA and Kukull, WA. Sleep disturbance in dementia with lewy bodies and Alzheimer's disease: a multicenter analysis. Dement Geriatr Cogn Disord, 31:239-246, 2011, PMC3085031.
  171. Bloudek, LM, Spackman, DE, Veenstra, DL, and Sullivan, SD. CDR State Transition Probabilities in Alzheimer's Disease with an without Cholinesterase Inhibitor Intervention in an Observational Cohort. J Alzheimers Dis, 24:599-607, 2011, PMC3593724.
  172. Carrasquillo, M, Olivia, B, Talisha, H, Ma, L, Bisceglio, G, Zou, F, Crook, J, Pankratz, V, Sando, S, Aasly, J, Barcikowska, M, Wszolek, Z, Dickson, D, Graff-Radford, N, Petersen, R, Morgan, K, Younkin, S. Replication of LOAD GWAS Associations. Alzheimers and Dementia, 7:S179, 2011. (Abstract)
  173. Demichele-Sweet, M A, Lopez, O L, Sweet, R A. Psychosis in Alzheimer's disease in the national Alzheimer's disease coordinating center uniform data set: clinical correlates and association with apolipoprotein e. Int J Alzheimers Dis, 2011:926597, 2011, PMC3065057.
  174. Frankel, A. Patterns of Cognitive Decline by Dementia Subtype. Doctoral Dissertation, Alliant International University, Los Angeles, 2011.
  175. Hanfelt, JJ, Wuu, J, Sollinger, AB, Greenway, MC, Lah, J, Levey, AI and Goldstein, FC. An Exploration of Subgroups of Mild Cognitive Impairment Based On Cognitive, Neuropsychiatric and Functional Features: Analysis of Data from the National Alzheimer's Coordinating Center. Am J Geriatric Psychiatry, 19:940-950, 2011, PMC3202691.
  176. Hermida, A, Seals, R, Levey, A, Steenland, K. Cognitive Decline and Depression in 29 US Alzheimer Disease Centers. Alzheimer's and Dementia, 7:S349-351, 2011. (Abstract)
  177. Johnson, DK, Watts, A, Chapin, BA, Anderson, R and Burns, JM. Neuropsychiatric Profiles in Dementia. Alzheimer Dis Assoc Disord, 25:326-332, 2011, PMC3218373.
  178. Jun, G, Buros, J, Narayan Vardarajan, B, Lunetta, K, Farrer, LA and The AD Genetics Consortium. Genome-wide scan suggested novel Alzheimer disease susceptibility genes by factoring influence of APOE. Alzheimer's and Dementia, 7:S186, 2011. (Abstract)
  179. Kaur, B, Harvey, D, DeCarli, C, Sabbagh, M and Olichney, J. Measurable Parkinsonism in Clinically Diagnosed Alzheimer's Disease: Associated with Mixed Neuropathologies. Neurology, 76:A622, 2011. (Abstract)
  180. Knopman, D, Weintraub, S and Pankratz, VS. Language and Behavior Domains Enhance the Value of the Clinical Dementia Rating Scale. Alzheimer's and Dementia, 7:293-299, 2011, PMC3096831.
  181. Kukic, V, Nan, B, Wang, X, Heidebrink, J, Barbas, N and Giordani, B. Type 2 diabetes, but not hypercholesterolemia, is related to decrements in cognitive functioning among patients with MCI. Alzheimer's and Dementia, 76:S270, 2011. (Abstract)
  182. Lau DT, Mercaldo ND, Shega JW, Rademaker A, Weintraub S. Functional decline associated with polypharmacy and potentially inappropriate medications in community-dwelling older adults with dementia. Am J Alzheimers Dis Other Demen, 26:606-615, 2011, PMC3298080.
  183. Lu, P, Saver, JL, Beigi, M, Vinters, H and Ringman, JM. Cognitive Predictors of Severe Cerebral Amyloid Angiopathy in Alzheimer's Disease Patients. Neurology, 76:A231, 2011. (Abstract)
  184. Martin, ER and The AD Genetics Consortium. Genome-wide Association Analyses Identifies Novel Loci Associated with the Onset Age Among Cases with Late-Onset Alzheimer's Disease. Alzheimer's and Dementia, 7:S188, 2011. (Abstract)
  185. Middleton LE, Grinberg LT, Miller B, Kawas C, Yaffe K. Neuropathologic features associated with Alzheimer disease diagnosis: age matters. Neurology, 77:1737-1744, 2011, PMC3208952.
  186. Naj AC, Jun G, Beecham GW, Wang LS, Vardarajan BN, Buros J, Gallins PJ, Buxbaum JD, Jarvik GP, Crane PK, Larson EB, Bird TD, Boeve BF, Graff-Radford NR, De Jager PL, Evans D, Schneider JA, Carrasquillo MM, Ertekin-Taner N, Younkin SG, Cruchaga C, Kauwe JS, Nowotny P, Kramer P, Hardy J, Huentelman MJ, Myers AJ, Barmada MM, Demirci FY, Baldwin CT, Green RC, Rogaeva E, George-Hyslop PS, Arnold SE, Barber R, Beach T, Bigio EH, Bowen JD, Boxer A, Burke JR, Cairns NJ, Carlson CS, Carney RM, Carroll SL, Chui HC, Clark DG, Corneveaux J, Cotman CW, Cummings JL, Decarli C, Dekosky ST, Diaz-Arrastia R, Dick M, Dickson DW, Ellis WG, Faber KM, Fallon KB, Farlow MR, Ferris S, Frosch MP, Galasko DR, Ganguli M, Gearing M, Geschwind DH, Ghetti B, Gilbert JR, Gilman S, Giordani B, Glass JD, Growdon JH, Hamilton RL, Harrell LE, Head E, Honig LS, Hulette CM, Hyman BT, Jicha GA, Jin LW, Johnson N, Karlawish J, Karydas A, Kaye JA, Kim R, Koo EH, Kowall NW, Lah JJ, Levey AI, Lieberman AP, Lopez OL, Mack WJ,. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet, 43:436-441, 2011, PMC3090745.
  187. Naj, AC, Jun, G and The AD Genetics Consortium. Genome-wide Association Study of Late-Onset Alzheimer Disease Identifies Disease-Associated Variants in MS4A4/MS4A6E, CD2AP, CD33, and EPHA1. Alzheimer's and Dementia, 7:S189-190, 2011. (Abstract)
  188. Nelson, PT, Head, E, Schmitt, FA, Jicha, GA, Abner, E, Smith, CD, Van Eldik, LJ, Kryscio, RJ and Scheff, SW. Alzheimer’s disease is not “brain aging”: neuropathological, genetic, and epidemiological human studies. Acta Neuropathol, 121:571-587, 2011, PMC3179861.
  189. Nelson, PT, Schmitt, FA, Lin, Y, Abner, EL, Jicha, GA, Patel, E, Thomason, PC, Neltner, JH, Smith, CD, Santacruz, KS, Sonnen, JA, Poon, LW, Gearing, M, Green, RC, Woodard, JL, Van Eldik, LJ, Kryscio, RJ. Hippocampal sclerosis in advanced age: clinical and pathological features. Brain, 134:1506-1518, 2011, PMC3097889.
  190. Ringman, JM, Saver, JL, Beigi, M, Lu, P and Vinters, H. Clinical Predictors of Severe Cerebral Amyloid Angiopathy in Alzheimer's Disease Patients. Neurology, 76:A662, 2011. (Abstract)
  191. Rosenberg, PB, Mielke, MM, Appleby, B, Oh, E, Leoutsakos, JM and Lyketsos, CG. Neuropsychiatric symptoms in MCI subtypes: the importance of executive dysfunction. Int J Geriatr Psychiatry, 26:364-372, 2011, PMC3204866.
  192. Sadak T, Borson S, Cochrane BB, Kukull W, Logsdon R, Herting JR. Dementia Diagnoses, Neuropsychiatric Symptoms and Physical Comorbidities. Western Institute of Nursing Research, 2011. (Abstract)
  193. Sayed, N and Diaz-Arrastia, R. Clinical and Pathologic Phenotype of Dementia after Traumatic Brain Injury (TBI). Alzheimer's and Dementia, 7:S750, 2011. (Abstract)
  194. Sayegh P, Knight BG. Differences in Predictors of a Dementia Diagnosis among Hispanic and nonHispanic White Outpatients. Gerontological Society of America (GSA) Meeting November, 2011. (Abstract)
  195. Shim, YS, Morris, JC, Buckles, VD. Clinicopathologic Study of Alzheimer's Disease: Alzheimer Mimic. World Congress of Neurology, 2011. (Abstract)
  196. Shirk SD, Mitchell MB, Shaughnessy LW, Sherman JC, Locascio JJ, Weintraub S, Atri A. A web-based normative calculator for the uniform data set (UDS) neuropsychological test battery. Alzheimer's research & therapy, 3:32, 2011, PMC3308021.
  197. Spiegel R, Berres M, Miserez AR, Monsch AU. The Placebo Group Simulation Approach (PGSA): An Alternative Study Design for Clinical Trials in Patients with Prodromal AD. CTAD Conference, San Diego November 3-5, 2011. (Abstract)
  198. Spiegel R. It really works! Confirmation of the ADNI-based Placebo Group Simulation Approach with NACC data. Alzheimer's and Dementia, 7:e64, 2011. (Abstract)
  199. Stratton, JH,. Diagnostic Accuracy of a Binary Test in the Presence of Two Types of Missing Values. Doctoral Dissertation, University of Connecticut, 2011.
  200. Thornton-Wells, TA, Torstenson, ES, Dudek, SM, Ritchie, MD, Martin, E, Pericak-Vance, MA and Haines, JL. Discovery and replication of gene-gene interactions in multiple independent datasets from the Alzheimer Disease Genetics Consortium. Alzheimer's and Dementia, 7:S195-196, 2011. (Abstract)
  201. Vardarajan, B, Jun, G, Buros, J, Lunetta, K, Farrer, LA and The AD Genetics Consortium. Identification of gene-gene interactions for Alzheimer disease using co-operative game theory. Alzheimer's and Dementia, 7:S196, 2011. (Abstract)
  202. Wang, LS, Lin, CF, Schellenberg, G and The AD Genetics Consortium. Distribution of copy number variations in Alzheimer's Disease. Alzheimer's and Dementia, 7:S271, 2011. (Abstract)
  203. Wang, LS, Valladares, O, Lin, CF, Buros, J, Naj, A, Farrer, L, Pericak-Vance, M, Schellenberg, G and The AD Genetics Consortium. The ADGC Genome Browser. Alzheimer's and Dementia, 7:S271, 2011. (Abstract)
  204. Yamout, K, Mungas, D and Reed, BR. Cardiovascular, Cerebrovascular, and Alzheimer's Disease and Cognition in an Autopsy Sample. Neurology, 76:A74, 2011. (Abstract)
2010 205. Bloudek, L, Spackman, E and Sullivan, SD. A Comparison of Transitions between Health States and Institutionalization among AD Patients vs Non-AD Dementia Patients Using the NACC-UDS Database. Value Health, 13:A108-A109, 2010. (Abstract)
  206. Cummings, J and Lee, C. Neuropathologic correlates of trial-related clinical assessments. Alzheimer's and Dementia, 6:S142, 2010. (Abstract)
  207. De Santi, S, Pirraglia, E, Ferris, SH, Morris, JC, Weintraub, S and Johnson, N. Robust norms for the ADC UDS cognitive test battery. Alzheimer's and Dementia, 6:S495-S496, 2010. (Abstract)
  208. Ebner, LL and Appleby, B. Neuropsychiatric Manifestations in Dementia: Difference Between Young Onset and Lat Onset Presentation. Alzheimer's and Dementia, 6:S341, 2010. (Abstract)
  209. Farrer, LA. US Alzheimer Disease Genetics Consortium: Organization and Results. Alzheimer's and Dementia, 6:S67, 2010. (Abstract)
  210. Hernandez, S, McClendon, MJ, Zhou, XH, Sachs, M and Lerner, AJ. Pharmacological treatment of Alzheimer's disease: effect of race and demographic variables. J Alzheimers Dis, 19:665-672, 2010, PMC2827609.
  211. Jun G, Naj AC, Beecham GW, Wang LS, Buros J, Gallins PJ, Buxbaum JD, Ertekin-Taner N, Fallin MD, Friedland R, Inzelberg R, Kramer P, Rogaeva E, St George-Hyslop P, Cantwell LB, Dombroski BA, Saykin AJ, Reiman EM, Bennett DA, Morris JC, Lunetta KL, Martin ER, Montine TJ, Goate AM, Blacker D, Tsuang DW, Beekly D, Cupples LA, Hakonarson H, Kukull W, Foroud TM, Haines J, Mayeux R, Farrer LA, Pericak-Vance MA, Schellenberg GD. Meta-analysis confirms CR1, CLU, and PICALM as alzheimer disease risk loci and reveals interactions with APOE genotypes. Arch Neurol, 67:1473-1484, 2010, PMC3048805.
  212. Kaur, B, Harvey, D, DeCarli, C, Sabbagh, M and Olichney, J. Comparison of extrapyramidal signs (EPS) to dementia severity in Alzheimer's disease (AD) and Dementia with Lewy Bodies (DLB). Alzheimer's and Dementia, 6:P2-174, 2010. (Abstract)
  213. Kielb SA, Okonkwo OC, Sur S, Kortte KB, Onyike CU. Education, Executive Functions and the Trajectory of Disability in Frontotemporal Dementia. Int'l Conference for Frontotemporal Dementia, 2010. (Abstract)
  214. Knopman, D, Weintraub, S and Pankratz, VS. Language and Behavior Domain Enhance the Value of the Clinical Dementia Rating Scale. Neurology, 74:A429-A430, 2010. (Abstract)
  215. Lau, DT, Mercaldo, ND, Harris, AT, Trittschuh, E, Shega, J and Weintraub, S. Polypharmacy and potentially inappropriate medication use among community-dwelling elders with dementia. Alzheimer Dis Assoc Disord, 24:56-63, 2010, PMC2837122.
  216. Middleton, LE, Grinberg, L, Kawas, CH, Miller, B and Yaffe, K. The Nueropathological Features Associated with Alzheimer's Disease Diagnosis in The Oldest Old Versus the Young Old. Alzheimer's and Dementia, 6:S108-S109, 2010. (Abstract)
  217. Nelson, PT, Jicha, GA, Kryscio, RJ, Abner, EL, Schmitt, FA, Cooper, G, Xu, LO, Smith, CD and Markesbery, WR. Low sensitivity in clinical diagnoses of dementia with Lewy bodies. J Neurol, 257:359-366, 2010, PMC2839040.
  218. Nelson, PT, Kukull, WA and Frosch, MP. Thinking outside the box: Alzheimer-type neuropathology that does not map directly onto current consensus recommendations. J Neuropathol Exp Neurol, 69:449-454, 2010, PMC2892786.
  219. Nelson, PT, Schmitt, FA, Jicha, GA, Kryscio, RJ, Abner, EL, Smith, CD, Van Eldik, LJ and Markesbery, WR. Association between male gender and cortical Lewy body pathology in large autopsy series. J Neurol, 257:1875-1881, 2010, PMC3040648.
  220. O'Bryant, SE, Lacritz, LH, Hall, J, Waring, SC, Chan, W, Khodr, ZG, Massman, PJ, Hobson, V and Cullum, CM. Validation of the new interpretive guidelines for the clinical dementia rating scale sum of boxes score in the national Alzheimer's coordinating center database. Arch Neurol, 67:746-749, 2010, PMC2888493.
  221. Petersen, RC, Gill, DP, Phillips, LE and Aisen, P. Early MCI as an Imaging Target: data from the National Alzheimer's Coordinating Center. Alzheimer's and Dementia, 6:S58, 2010. (Abstract)
  222. Rosenberg, PB and Lyketsos, CG. A New Concept: The Concept of Mild Behavioral Impairment (MBI). Emotions Et Cognition Dans Les Maladies Neurologiques, Marseille France, 2010. (Abstract)
  223. Sayed, N and Diaz-Arrastia, R. Clinical Phenotype of Dementia after Traumatic Brain Injury (TBI). Neurology, 74:A139, 2010. (Abstract)
  224. Steenland, K, Macneil, J, Bartell, S and Lah, J. Analyses of diagnostic patterns at 30 Alzheimer's disease centers in the US. Neuroepidemiology, 35:19-27, 2010, PMC2919431.
  225. Tartaglia, MC, Mehta, KM, Hu, B, Miller, BL and Boxer, AL. Medication Use Differs in Alzheimer's disease and Frontotemporal dementia. Alzheimer's and Dementia, 6:S589-S590, 2010. (Abstract)
  226. Teng, E, Becker, BW, Woo, E, Cummings, JL and Lu, PH. Subtle Deficits in Instrumental Activities of Daily Living in Subtypes of Mild Cognitive Impairment. Dement Geriatr Cogn Disord, 30:189-197, 2010, PMC2948658.
  227. Teng, E, Becker, BW, Woo, E, Knopman, DS, Cummings, JL and Lu, PH. Utility of the Functional Activities Questionnaire for Distinguishing Mild Cognitive Impairment From Very Mild Alzheimer Disease. Alzheimer Dis Assoc Disord, 24:348-353, 2010, PMC2997338.
  228. Walters, GD. Dementia: Continuum or distinct entity?. Psychol Aging, 25:534-544, 2010, PMC2943994.
  229. Yamout, K. AD Pathology, Vascular Neuropathology and Cognition. Intl Neuropsychology Society Meeting, 2010. (Abstract)
2009 230. Acevedo, A, Krueger, KR, Navarro, E, Ortiz, F, Manly, JJ, Padilla-Velez, MM, Weintraub, S, Lopez, OL and Mungas, D. The Spanish translation and adaptation of the Uniform Data Set of the National Institute on Aging Alzheimer's Disease Centers. Alzheimer Dis Assoc Disord, 23:102-109, 2009, PMC2963171.
  231. Lau, DT, Mercaldo, ND, Rademakers, R, Shega, J and Weintraub, S. Cognitive, functional, and behavioral decline associated with polypharmacy and potentially inappropriate medication use in community-dwelling elders with and without dementia. American Public Health Association, 137th Annual Conference Philadelphia, PA, 2009. (Abstract)
  232. McClendon, MJ, Hernandez, S, Smyth, KA and Lerner, AJ. Memantine and acetylcholinesterase inhibitor treatment in cases of CDR 05 or questionable impairment. J Alzheimers Dis, 16:577-583, 2009, PMC2827605.
  233. Nelson, PT, Abner, EL, Schmitt, FA, Kryscio, RJ, Jicha, GA, Santacruz, K, Smith, CD, Patel, E and Markesbery, WR. Brains With Medial Temporal Lobe Neurofibrillary Tangles But No Neuritic Amyloid Plaques Are a Diagnostic Dilemma But May Have Pathogenetic Aspects Distinct From Alzheimer Disease. J Neuropathol Exp Neurol, 68:774-784, 2009, PMC2725359.
  234. Nelson, PT, Kryscio, RJ, Jicha, GA, Abner, EL, Schmitt, FA, Xu, LO, Cooper, G, Smith, CD and Markesbery, WR. Relative preservation of MMSE scores in autopsy-proven dementia with Lewy bodies. Neurology, 73:1127-1133, 2009, PMC2764396.
  235. Spackman DE. Measuring Progression in Alzheimer's Disease: 'Dependence' as a Health Outcome and Transition Probabilities Between Stages of Disease, Institutionalization and Death. Doctoral Dissertation, University of Washington, 2009.
  236. Webster JA, Gibbs JR, Clarke J, Ray M, Zhang W, Holmans P, Rohrer K, Zhao A, Marlowe L, Kaleem M, McCorquodale DS, 3rd, Cuello C, Leung D, Bryden L, Nath P, Zismann VL, Joshipura K, Huentelman MJ, Hu-Lince D, Coon KD, Craig DW, Pearson JV, Heward CB, Reiman EM, Stephan D, Hardy J, Myers AJ. Genetic control of human brain transcript expression in Alzheimer disease. Am J Hum Genet, 84:445-458, 2009, PMC2667989.
  237. Weintraub S, Salmon D, Mercaldo N, Ferris S, Graff-Radford NR, Chui H, Cummings J, DeCarli C, Foster NL, Galasko D, Peskind E, Dietrich W, Beekly DL, Kukull WA, Morris JC. The Alzheimer's Disease Centers' Uniform Data Set (UDS): the neuropsychologic test battery. Alzheimer Dis Assoc Disord, 23:91-101, 2009, PMC2743984.
2008 238. Becker, B, Lu, P, Woo, E, Kim, M and Cummings, J. Insight into memory and mood functioning in amnestic mild cognitive impairment. 133rd Annual Meeting of the American Neurological Association, Salt Lake City, UT, 2008. (Abstract)
  239. Hong, MG, Myers, AJ, Magnusson, PK and Prince, JA. Transcriptome-wide assessment of human brain and lymphocyte senescence. PLoS ONE, 3:e3024, 2008, PMC2515343.
  240. Ishihara-Paul, L, Viswanathan, A, Allen, J, Hyman, B, Betensky, R, Weil, J, Blacker, D and Irizarry, M. P30 use of an US claims database and an US Alzheimer's Disease registry to assess clinical trial eligibility criteria. Health and Aging, 12:543, 2008. (Abstract)
  241. Maddox, RA, Mercaldo, ND, Deitrich, WD, Holman, RC, Gambetti, P, Harvey, AR, Schonberger, LB, Kukull, WA and Belay, ED. Clinically unrecognized cases of prion disease in the National Alzheimer's Coordinating Center Database. Prion 2008 conference Madrid Spain, 2008. (Abstract)
  242. Steenland, K, Macneil, J and Lah, J. Analyses of diagnostic patterns at 30 Alzheimer Disease Research Centers in the US. 10th Int'l Symposium on Neurobehavioral Methods and Effects in Environmental and Occupational Health (NEUREOH), San Jose, Costa Rica, 2008. (Abstract)
  243. Teng, E, Becker, B, Woo, E, Knopman, D, Cummings, H, Mendez, M and Lu, P. Utility of the functional activities questionnaire for distinguishing mild cognitive impairment from mild Alzheimer's disease. J Int Neuropsychol Soc, 14:259, 2008. (Abstract)
  244. Teng, E, Becker, B, Woo, E, Yau, A, Cumming, J, Mendez, M and Lu, P. Instrumental activities of daily living in subtypes of mild cognitive impairment. J Int Neuropsychol Soc, 13:259-260, 2008. (Abstract)
  245. Webster JA, Myers AJ, Pearson JV, Craig DW, Hu-Lince D, Coon KD, Zismann VL, Beach T, Leung D, Bryden L, Halperin RF, Marlowe L, Kaleem M, Huentelman MJ, Joshipura K, Walker D, Heward CB, Ravid R, Rogers J, Papassotiropoulos A, Hardy J, Reiman EM, Stephan DA. Sorl1 as an Alzheimer's disease predisposition gene?. Neurodegener Dis, 5:60-64, 2008.
  246. Weintraub, S, Mercaldo, N, Harris, A and Lau, D. Polypharmacy among Community-Dwelling Elderly Patients with Dementia: Analysis of the National Alzheimer's Coordinating Center Uniform Data Set. Alzheimer's and Dementia, 4:T454, 2008. (Abstract)
2007 247. Myers AJ, Gibbs JR, Webster JA, Rohrer K, Zhao A, Marlowe L, Kaleem M, Leung D, Bryden L, Nath P, Zismann VL, Joshipura K, Huentelman MJ, Hu-Lince D, Coon KD, Craig DW, Pearson JV, Holmans P, Heward CB, Reiman EM, Stephan D, Hardy J. A survey of genetic human cortical gene expression. Nat Genet, 39:1494-1499, 2007.
  248. Weiner, MF, Hynan, LS, Beekly, D, Koepsell, TD and Kukull, WA. Comparison of Alzheimer's Disease in American Indians, Whites, and African Americans. Alzheimer's and Dementia, 3:211-216, 2007.
2006 249. Morris, JC, Weintraub, S, Chui, HC, Cummings, J, Decarli, C, Ferris, S, Foster, NL, Galasko, D, Graff-Radford, N, Peskind, ER, Beekly, D, Ramos, EM and Kukull, WA. The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer Dis Assoc Disord, 20:210-216, 2006.
  250. Morris, JC. Uniform Data Set (UDS). Alzheimer’s and Dementia, 2:S261-S262, 2006. (Abstract)
  251. Noda, A, Kraemer, HC, Taylor, JL, Schneider, B, Ashford, JW and Yesavage, JA. Strategies to reduce site differences in multisite studies: a case study of Alzheimer disease progression. Am J Geriatr Psychiatry, 14:931-938, 2006.
2005 252. Chow, TW, Hodges, JR, Dawson, KE, Miller, BL, Smith, V, Mendez, MF and Lipton, AM. Referral patterns for syndromes associated with frontotemporal lobar degeneration. Alzheimer Dis Assoc Disord, 19:17-19, 2005, PMC1578638.
  253. Honig, LS, Kukull, W and Mayeux, R. Atherosclerosis and AD: analysis of data from the US National Alzheimer's Coordinating Center. Neurology, 64:494-500, 2005.

SAS Output

NACC Personnel: (TOTAL of 105)

2014 1. Besser L, Monsell S, Heller K, Litvan I, Kukull W. Mild Cognitive Impairment among Parkinson’s Disease subjects in the Uniform Data Set. AAIC 2014, submitted 2014. (Abstract)
  2. Besser LM, Gill DP, Monsell SE, Brenowitz W, Meranus DH, Kukull W, Gustafson DR. Body Mass Index, Weight Change, and Clinical Progression in Mild Cognitive Impairment and Alzheimer Disease. Alzheimer Dis Assoc Diord, 28:36-43, 2014, PMC3945175.
  3. Brenowitz WD, Kukull WA, Beresford SA, Monsell SE, Williams EC. Social Relationships and Risk of Incident Mild Cognitive Impairment in US Alzheimer's Disease Centers. Alzheimer Dis Assoc Disord, in press 2014, NIHMS561898.
  4. Monsell SE, Besser LM, Heller KB, Checkoway H, Litvan I, Kukull WA. Clinical and pathologic presentation in Parkinson’s disease by Apolipoprotein e4 allele status. Parkinsonism & related disorders, in press 2014, NIHMS569057.
  5. Monsell SE, Caselli RJ, Kukull WA, Beach TG, Montine TJ, Reiman EM. APOE4 non-carriers with the clinical diagnosis of Alzheimer’s dementia and minimal amyloid histopathology. AAIC 2014, submitted 2014. (Abstract)
  6. Monsell SE, Mock C, Hassenstab J, Roe CM, Cairns NJ, Morris JC, Kukull WK.. Neuropsychological changes in asymptomatic persons with Alzheimer’s disease neuropathology. Neurology, submitted 2014.
2013 7. Besser L, Bristow KE, Monsell S, Kukull WA. Neuropsychological test scores in English and Spanish speakers with normal cognition. Alzheimer Dis Assoc Disord, submitted 2013.
  8. Besser LM, Gill DP, Hubbard RA, Monsell SE, Heller KB, Koepsell TD, Petrella RJ, Knopman DS, Kukull W. Differences in Rate of Clinical Progression of Three Dementia Types. Alzheimers and Dementia, submitted 2013.
  9. Besser LM, Gill DP, Monsell SE, Brenowitz W, Meranus D, Gustafson D, Kukull W. Body Weight Change and Clinical Progression in Mild Cognitive Impairment and Alzheimer's Disease. Neurodegener Dis, 11(S1), 2013. (Abstract)
  10. Besser LM, Hawes SE, Bristow KE, Monsell SE, Kukull WA. Pulse Pressure and Atherosclerosis, Arteriolosclerosis, and Cortical Microinfarcts in Individuals with Clinical Alzheimer’s Disease.. Alzheimers and Dementia, 9:P441, 2013. (Abstract)
  11. Brenowitz WD, Monsell SE, Kukull WA, Nelson PT. Hippocampal sclerosis of aging, a key potential AD confounder: the NACC experience. Alzheimers and Dementia, 9:P542, 2013. (Abstract)
  12. Brenowitz WD, Monsell SE, Schmitt FA, Kukull WA, Nelson PT. Hippocampal sclerosis of aging is a key Alzheimer’s disease mimic: clinical-pathologic correlations and comparisons with both Alzheimer’s disease and non-tauopathic frontotemporal lobar degeneration. J Alzheimers Dis, in press 2013, NIHMS532961.
  13. Brenowitz WD, Nelson PT, Besser LM, Bristow KE, Kukull WA. Cerebral Amyloid Angiopathy and its Co-occurrence with Alzheimer's Disease in the National Alzheimer's Coordinating Center Neuropathology Data Set. Alzheimers and Dementia, 9:P433, 2013. (Abstract)
  14. Bristow KE, Besser LM, Monsell SE, Brenowitz W, Hawes SE, Kukull WA. Consensus Diagnosis and Predictors of Diagnostic Accuracy in the National Alzheimer's Disease Centers. Alzheimers and Dementia, 9:P321, 2013. (Abstract)
  15. Chen B, Zhou A. Generalized Partially Linear Models for Incomplete Longitudinal Data In the Presence of Population-Level Information. Biometrics, 69:386-395, 2013, PMC3715115.
  16. Chen, B and Zhou, A. A Correlated Random Effects Model for Non-homogeneous Markov Process with Nonignorable Missingness. J Multivariate Analysis, 117:13-Jan, 2013, PMC3697104.
  17. Gill DP, Hubbard RA, Koepsell TD, Borrie M, Petrella RJ, Knopman D, Kukull WA. Differences in rate of functional decline across three dementia types. Alzheimer's and Dementia, in press 2013, PMC3766452.
  18. Koepsell TD, Gill DP, Chen B. Stability of Clinical Etiologic Diagnosis in Dementia and Mild Cognitive Impairment: Results from a Multi-Center Longitudinal Database. Am J Alzheimers Dis Other Demen, 28:750-758, 2013, PMC3876285.
  19. Kukull W, Monsell S, Besser L, Bristow K, Beekly D, Mock C, Hawes H. Comparison of Motor Symptoms in MCI by Underlying Disease Process. Neurodegener Dis, 11(S1), 2013. (Abstract)
  20. Liu D, Zhou A. ROC Analysis in Biomarker Combination with Covariate Adjustment. Academic Radiology, 20:874-882, 2013, PMC3682803.
  21. Liu, D and Zhou, XH. Covariate adjustment in estimating the area under ROC curve with partially missing gold standard. Biometrics, 69:91-100, 2013, PMC3622116.
  22. Meranus D, Kukull W. Antithrombotic medication use and dementia incidence in a longitudinal cohort with mild cognitive impairment and atrial fibrillation. Alzheimers and Dementia, 9:P612, 2013. (Abstract)
  23. Monsell SE, Mock C, Roe CM, Ghoshal N, Morris JC, Cairns NJ, Kukull W. Comparison of symptomatic and asymptomatic persons with Alzheimer’s disease neuropathology. Neurology, 80:2121-2129, 2013, PMC3716351.
  24. Monsell SM, Bristow KE, Besser LM, Checkoway H, Litvan I, Kukull WA. APOE e4 and clinical progression in Parkinson's disease. Alzheimers and Dementia, 9:P738-739, 2013. (Abstract)
  25. Sachs MC, Zhou XH. Partial summary measures of the predictiveness curve. Biometrical Journal, 55:589-602, 2013, PMC3806283.
  26. Wang L, Zhou X-H. Causal Inference with Truncation by Death in Observational Study. The Western North American Region of the International Biometric Society Annual Meeting, Los Angeles, CA, 2013. (Abstract)
  27. Wang L, Zhou XH, Kukull W. Are some individuals immune to dementia?. Alzheimers and Dementia, 9:P617-618, 2013. (Abstract)
  28. Wang Z, Zhou A. Latent class regression model for assessment of diagnostic tests in the absence of a gold standard, with accommodation for covariate information. Joint Statistical Meeting Montreal, Canada, 2013. (Abstract)
2012 29. Beekly D, Monsell S, Besser L, Gill D, Robichaud E, Knopman D, Kukull W. The NACC FTLD Module data. Dement Geriatr Cogn Disord, 34 (Suppl 1), 2012. (Abstract)
  30. Besser LM, Monsell S, Kukull WA. Comparison of Neuropsychological Test Scores among English and Spanish Speakers in a Multi-regional Sample of Cognitively Normal Subjects. Alzheimers and Dementia, 8:P548, 2012. (Abstract)
  31. Brenowitz W, Monsell S, Gill D, Kukull W. Neuropsychiatric symptoms in mild Alzheimer’s disease: the influence of research study informants. Alzheimers and Dementia, 8:P382-P383, 2012. (Abstract)
  32. Chen B, Qin J. A new estimation with minimum trace of asymptotic covariance matrix for incomplete longitudinal data with a surrogate process. Stat Med, in press 2012, PMC3808493.
  33. Chen, B and Zhou, A. A Latent-Variable Marginal Method for Multi-Level Incomplete Binary Data. Stat Med, 31:3211-3222, 2012, PMC3631603.
  34. Chen, B, Yi, G, Cook, R and Zhou, XH. Marginal Methods for Clustered Longitudinal Binary Data with Incomplete Covariates. J of Stat Planning and Inference, 142:2819-2831, 2012, PMC3690662.
  35. Chen, B, Zhou, XH and Chan, G. Pseudo-empirical Likelihood-Based Method Using Calibration for Longitudinal Data with Drop-Out. Scand J Statistics, submitted 2012.
  36. Gill DP, Hubbard RA, Koepsell TD, Knopman DS, Kukull WA. Sex differences in rate of progression of three dementia types. Alzheimers and Dementia, 8:P622-P623, 2012. (Abstract)
  37. Koepsell TD, Monsell SE. Reversion from mild cognitive impairment to normal or near-normal cognition: risk factors and prognosis. Neurology, 79:1591-1598, 2012, PMC3475624.
  38. Kukull W, Knopman D, Mesulam M, Grossman M, Miller B, Weintraub S, Kramer J, Rankin K, Rosen H, Hillis A, Boeve B, Mendez M, Phelps C, Morris J. Standardized data collection and diagnostic formulation for FTLD Clinical Exam: The FTLD Module. Dement Geriatr Cogn Disord, 34 (Suppl 1), 2012. (Abstract)
  39. Kukull WA, Ganguli M. Generalizability: The trees, the forest, and the low-hanging fruit.. Neurology, 78:1886-1891, 2012, PMC3369519.
  40. Kukull WA. An apple a day to prevent Parkinson disease: reduction of risk by flavonoids. Neurology, 78:1112-1113, 2012, PMC Journal - In Process.
  41. Meranus D, Monsell S, Thomas G, Kukull W. Cholinesterase Inhibitors and Memantine Use in the National Alzheimer's Coordinating Center's Uniform Data Set: A Longitudinal Assessment of Real-World Medication Use in Dementia. Alzheimers and Dementia, 8:P711, 2012. (Abstract)
  42. Monsell SE, Liu D, Weintraub S, Kukull WA. Comparing measures of decline to dementia in amnestic MCI subjects in the National Alzheimer's Coordinating Center (NACC) Uniform Data Set. Int Psychogeriatr, 24:1553-1560, 2012, PMC3614357.
  43. Zhou XH, Duan X. Quantile Regression-based Covariate-Specific ROC Curves. WFN Annual Regional North American Meeting, 2012. (Abstract)
2011 44. Chen, B and Zhou, A. Doubly Robust Estimates for Binary Longitudinal Data Analysis with Missing Response and Missing Covariates. Biometrics, 67:830-842, 2011, PMC3652597.
  45. Chen, B and Zhou, XH. Non-homogeneous Markov process models with informative observations with an application to Alzheimer's disease. Biometrical J, 53:444-463, 2011, PMC3631600.
  46. Chen, B and Zhou, XHA. Non-Homogeneous Markov Process Models with Informative Observation Times, with an Application to Alzheimer's Disease. Alzheimer's and Dementia, 7:S366, 2011. (Abstract)
  47. Gill, DP, Koepsell, TD, Hubbard, RA and Kukull, WA. Risk of decline in functional activities in dementia with lewy bodies and Alzheimer disease. Alzheimer Dis Assoc Disord, 25:17-23, 2011, PMC3053143.
  48. Hubbard, RA and Zhou, XH. A comparison of non-homogeneous Markov regression models with application to Alzheimer's disease progression. J Applied Stat, 38:2313-2326, 2011, PMC3299197.
  49. Koepsell, T and Monsell, S. Characterizing Individuals who Revert from Mild Cognitive Impairment to Normal or Near-Normal Cognition. Alzheimer's and Dementia, 7:S532, 2011. (Abstract)
  50. Koepsell, T and Monsell, S. Testing the First-Order Markov Assumption in Homogeneous Markov Modeling of Transition Probabilities between Cognitive States. Alzheimer's and Dementia, 7:S351-352, 2011. (Abstract)
  51. Liu, D and Zhou, A. A Model for Adjusting for Nonignorable Verification Bias in Estimation of ROC Curve and Its Area with Likelihood-Based Approach. Biometrics, 66:1119-1128, 2011, PMC3618959.
  52. Liu, D and Zhou, A. Semiparametric estimation of the covariate-specific ROC curve in presence of ignorable verification bias. Biometrics, 67:906-16, 2011, PMC3618959.
  53. Monsell, S, Liu, D, Cosentino, S, Weintraub, S and Kukull, WA. Comparing Global Measures of Cognitive Decline in Amnestic MCI Subjects in the National Alzheimer's Coordinating Center (NACC) Uniform Data Set. Alzheimer's and Dementia, 7:S536, 2011. (Abstract)
  54. Phillips, LE, Roe, C and Monsell, SE. Age, Education and Cognitive Impairment in an Autopsy Series of Subjects with Tau-positive Neuropathological Frontotemporal Lobar Degeneration in the National Alzheimer's Coordinating Center (NACC) Da. Alzheimer's and Dementia, 7:S757, 2011. (Abstract)
2010 55. Beekly, D, Koepsell, T, Phillips, L, Jacka, M, Hubbard, J, Wu, J, Morris, J, Phelps, C and Kukull, WA. The NACC Uniform Data Set. Alzheimer's and Dementia, 6:S457, 2010. (Abstract)
  56. Chen, B and Zhou, A. Marginal Method for Multi-level Incomplete Binary Data. Joint Statistical Meeting 2010, 2010. (Abstract)
  57. Ganguli, M and Kukull, WA. Lost in translation: epidemiology, risk, and Alzheimer disease. Arch Neurol, 67:107-111, 2010, PMC2806646.
  58. Gill, D, Koepsell, T, Hubbard, RA and Kukull, WA. Risk of 1-year Decline in Functional Activities in Dementia with Lewy Bodies and Alzheimer's Disease. Neurology, 74:A431, 2010. (Abstract)
  59. Koepsell, T, Gill, D and Chen, B. Stability of Dementia Diagnosis in the National Alzheimer's Coordinating Center (NACC) Uniform Data Set. Alzheimer's and Dementia, 6:S365, 2010. (Abstract)
  60. Phillips, L, Roe, CM, Gill, D, Koepsell, TD and Morris, JC. Family History, Demographics, and Genetic Characteristics of Symptomatic and Non-Symptomatic Subjects with Neuropathological Alzheimer's Disease in the National Alzheimer's Coordinating Center (NACC). Alzheimer's and Dementia, 6:S126, 2010. (Abstract)
  61. Sachs, M. Factors Associated with Brain Autopsy in a Large Sample of Decedents. Alzheimer's and Dementia, 6:S460-S461, 2010. (Abstract)
2009 62. Gill, DP, Koepsell, TD and Kukull, WA. Risk of Decline in Functional Activities in Dementia with Lewy Bodies and Alzheimer's Disease. Neuroepidemiology, 33:71, 2009. (Abstract)
  63. Hsieh, HN, Su, HY and Zhou, XH. Interval estimation for the difference in paired areas under the ROC curves in the absence of a gold standard test. Stat Med, 28:3108-3123, 2009, PMC2812057.
  64. Kukull, WA, Phillips, L, Gill, D, Wu, J, Sachs, M, Beekly, D and Koepsell, T. Primary Neuropathologic Diagnosis and Co-Occurrence of Other Neuropathologic Features: Results from the National Alzheimer's Coordinating Center (NACC). Alzheimer's and Dementia, 5:P71-P72, 2009. (Abstract)
  65. Kukull, WA. Commentary on a roadmap for the prevention of dementia II: Leon Thal Symposium 2008 "Big Asks": what can be changed to increase and speed progress on Alzheimer's disease research and treatment?". Alzheimer’s and Dementia, 5:137-139, 2009, PMC3744190.
  66. Longstreth, WT, Jr, Sonnen, JA, Koepsell, TD, Kukull, WA, Larson, EB and Montine, TJ. Associations between microinfarcts and other macroscopic vascular findings on neuropathologic examination in 2 databases. Alzheimer Dis Assoc Disord, 23:291-294, 2009, PMC2919361.
  67. Phillips, LE, Koepsell, TD and Kukull, WA. Refusal and Passive Loss-to-Follow-up in the NIA Alzheimer's Disease Program Uniform Data Set. Neurology, 72:A479-A480, 2009. (Abstract)
2008 68. Chi, YY and Zhou, XH. Receiver operating characteristic surfaces in the presence of verification bias. Appl Stat, 57:23-Jan, 2008.
  69. Hubbard, R and Zhou, XH. A non-homogeneous Markov process model for Alzheimer's disease progression. Int Biometrics Society, 159, 2008. (Abstract)
  70. Hubbard, R. Identifying risk factors for conversion between normal cognition, MCI, and dementia using Markov processes. Alzheimer's and Dementia, 4:T675-676, 2008. (Abstract)
  71. Hubbard, RA and Zhou, A. Modeling Risk Factors for Alzheimer's Disease Progression Using a Nonhomogeneous Markov Process. Joint Statistical Meeting, 193, 2008. (Abstract)
  72. Koepsell, TD, Kurland, BF, Harel, O, Johnson, EA, Zhou, XH and Kukull, WA. Education, cognitive function, and severity of neuropathology in Alzheimer disease. Neurology, 70:1732-1739, 2008.
  73. Mercaldo, N, Harris, AT, Weintraub, S and Lau, DT. Potentially Inappropriate Medication Use Among Community-Dwelling Elderly Patients With Dementia In US Alzheimer's Disease Centers. 136th Annual Conference, Gerontological Health Section, 2008. (Abstract)
  74. Sachs, M and Koepsell, TD. Factors Associated with Brain Autopsy in a Large Multi-Center Sample of Decedents: A Multivariate Analysis. Alzheimer's and Dementia, 4:T712, 2008. (Abstract)
2007 75. Beekly, DL, Ramos, EM, Lee, WW, Deitrich, WD, Jacka, ME, Wu, J, Hubbard, JL, Koepsell, TD, Morris, JC and Kukull, WA. The National Alzheimer's Coordinating Center (NACC) database: the Uniform Data Set. Alzheimer Dis Assoc Disord, 21:249-258, 2007.
  76. Deitrich W, Beekly D, Lee W, Koepsell T, Kukull W. Web-based Data Quality Assurance Reports at the National Alzheimer’s Coordinating Center (NACC). Proceedings of the SAS® Global Forum 2007 Conference; 2007; Cary, NC: SAS Institute Inc, 2007.
  77. Harel, O and Zhou, XH. Multiple imputation for the comparison of two screening tests in two-phase Alzheimer studies. Stat Med, 26:2370-2388, 2007.
  78. Harel, O and Zhou, XH. Multiple imputation: review of theory, implementation and software. Stat Med, 26:3057-3077, 2007.
  79. Koepsell, TD, Chi, YY, Zhou, XH, Lee, WW, Ramos, EM and Kukull, W. An alternative method for estimating efficacy of the AN1792 vaccine for Alzheimer's disease. Neurology, 68:A169-A170, 2007. (Abstract)
  80. Koepsell, TD, Chi, YY, Zhou, XH, Lee, WW, Ramos, EM and Kukull, WA. An alternative method for estimating efficacy of the AN1792 vaccine for Alzheimer disease. Neurology, 69:1868-1872, 2007.
2006 81. Beekly, DL, Ramos, EM, Jacka, ME, Deitrich, WD, Hubbard, JD, Wu, J, Lee, WW, JC, M and Kukull, WA. The National Alzheimer's Coordinating Center's Data Submissions System and Database. Alzheimer's and Dementia, 2:S267, 2006. (Abstract)
  82. Harel, O and Zhou, XH. Multiple imputation for correcting verification bias. Stat Med, 25:3769-3786, 2006.
  83. Kukull, WA, Dickson, DW, Montine, TJ, Ramos, EM, Zhang, A and D, KT. Lewy body (LB) pathology and clinical diagnoses in the National Alzheimer's Coordinating Center (NACC) database. Alzheimer’s and Dementia, 2:S430-431, 2006. (Abstract)
  84. Kukull, WA. The growing global burden of dementia. Lancet Neurol, 5:199-200, 2006.
  85. Lee, WW, Beekly, DL, Ramos, EM, Jacka, ME, Deitrich, WD, Hubbard, JL, Wu, J, Morris, JS and Kukull, WA. Using the web to collect data for Alzheimer's research. 11th World Congress on Internet & Medicine, 2006. (Abstract)
  86. Zhang, Z, Ramos, E, Zhou, A, Koepsell, T and Kukull, WA. Agreement between neuropathologic criteria for the diagnosis of Alzheimer's disease. Neurology, 66:283, 2006. (Abstract)
2005 87. Harel, O, Koepsell, T, Kukull, WA and Zhou, XH. Correcting for verification bias in the assessment of the accuracy of the clinical diagnosis of AD. Neurology, 64:A69, 2005. (Abstract)
  88. Koepsell, T, Kurland, BF, Zhou, XH, Harel, O and Kukull, WA. Education, cognitive function, and severity of neuropathology in Alzheimer's disease. 7th Intl Conference AD/PD Book of Abstracts, 67, 2005. (Abstract)
  89. Kurland, BF and Heagerty, PJ. Directly parameterized regression conditioning on being alive: analysis of longitudinal data truncated by deaths. Biostatistics, 6:241-258, 2005.
  90. Kurland, BF, Kukull, WA, Koepsell, TD, Zhou, XH, Ramos, EP and Harel, O. Impact of time scale choice on rate of cognitive decline: a case study from the National Alzheimer's Coordinating Center Minimum Data Set. Alzheimer's and Dementia, 1:S33-34, 2005. (Abstract)
  91. Ramos, EM, Koepsell, TD, Kurland, BF, Harel, O, Zhou, XH and Kukull, WA. Pathology of subjects clinically diagnosed with vascular dementia. Vas Cog 2005 Abstract Book, 22, 2005. (Abstract)
2004 92. Beekly, DL, Ramos, EM, van Belle, G, Deitrich, W, Clark, AD, Jacka, ME and Kukull, WA. The National Alzheimer's Coordinating Center (NACC) Database: an Alzheimer disease database. Alzheimer Dis Assoc Disord, 18:270-277, 2004.
  93. Fitzpatrick, AL, Kukull, WA, Koepsell, T and Higdon, R. Survival by Type of Dementia: Data from the National Alzheimer's Coordinating Center. Neurology, 62:A452, 2004. (Abstract)
  94. Fitzpatrick, AL, Kukull, WA, Koepsell, TD, Higdon, R, Pfeiffer, E and Kurland, B. Depression within dementia subtypes: data from the National Alzheimer's Coordinating Center. Neurobiol, 25:479, 2004. (Abstract)
  95. Higdon, R, Foster, NL, Koeppe, RA, DeCarli, CS, Jagust, WJ, Clark, CM, Barbas, NR, Arnold, SE, Turner, RS, Heidebrink, JL and Minoshima, S. A comparison of classification methods for differentiating fronto-temporal dementia from Alzheimer's disease using FDG-PET imaging. Stat Med, 23:315-326, 2004.
  96. Koepsell, TD, Kukull, WA, Beekly, D, van Belle, G, Higdon, R, Fitzpatrick, A and Kurland, B. Public-use data from NACC. Neurobiol Aging, 25:386, 2004. (Abstract)
  97. Kukull, WA. Perspectives on shared genetic contributions for Parkinson disease and Alzheimer disease. Arch Neurol, 61:1007-1008, 2004.
  98. Kurland, BF and Heagerty, PJ. Marginalized transition models for longitudinal binary data with ignorable and non-ignorable drop-out. Stat Med, 23:2673-2695, 2004.
  99. Pfeiffer, EM, Higdon, R, Koepsell, TD, Fitzpatrick, AL, Beekly, DL and Kukull, WA. Examining the agreement between CERAD and NIA/Regan Institute neuropathological criteria for the diagnosis of Alzheimer's disease. Neurobiol Aging, 25:134, 2004. (Abstract)
2003 100. Higdon, R, Beekly, D, Pfeiffer, EA, van Belle, G and Kukull, WA. Sensitivity and specificity of Alzheimer's disease and dementia diagnoses for patients enrolled in NIA funded Alzheimer's Disease Centers. Neurology, 60:A309-A310, 2003. (Abstract)
  101. Kurland BF, Heagerty PJ. Targets of inference for longitudinal data censored by dropout and death. In: 2003 Proceedings of the American Statistical Association, Biometrics Section CD-ROM, 2003.
2002 102. Kukull, WA and Bowen, JD. Dementia epidemiology. Med Clin North Am, 86:573-590, 2002.
  103. Kukull, WA, Higdon, R, Bowen, JD, McCormick, WC, Teri, L, Schellenberg, GD, van Belle, G, Jolley, L and Larson, EB. Dementia and Alzheimer disease incidence: a prospective cohort study. Arch Neurol, 59:1737-1746, 2002.
2001 104. Kukull, WA. The association between smoking and Alzheimer's disease: effects of study design and bias. Biol Psychiatry, 49:194-199, 2001.
2000 105. Kukull, WA and Ganguli, M. Epidemiology of dementia: concepts and overview. Neurol Clin, 18:923-950, 2000.

SAS Output

NACC Funded Projects (by project): (TOTAL of 174)

SAS Output

Principal Investigator: Teresa Gomez-Isla MD, PhD (NACC Project #2011-03)

Title: Are Some Human Brains Able to Resist Alzheimer's Pathology?

Lead Institutions: Massachusetts ADRC

1. Perez-Nievas BG, Stein TD, Tai HC, Dols-Icardo O, Scotton TC, Barroeta-Espar I, Fernandez-Carballo L, de Munain EL, Perez J, Marquie M, Serrano-Pozo A, Frosch MP, Lowe V, Parisi JE, Petersen RC, Ikonomovic MD, Lopez OL, Klunk W, Hyman BT, Gomez-Isla T. Dissecting phenotypic traits linked to human resilience to Alzheimer's pathology. Brain, 136:2510-2526, 2013, PMC3722351.

SAS Output

Principal Investigator: Brent Small (NACC Project #2008-01)

Title: Changes in Cognitive performance in Preclinical AD: A Collaborative Analysis

Lead Institutions: Florida ADC

2. Small, BJ, Dixon, RA, McArdle, JJ. Tracking Cognition–Health Changes From 55 to 95 Years of Age. J Gerontol, 66:i153-161, 2011, PMC3132770.

SAS Output

Principal Investigator: John H. Growdon, MD (NACC Project #2007-01)

Title: Lewy Body Diseases Imaged with PiB

Lead Institutions: Massachusetts ADRC

3. Gomperts SN, Johnson KA, Growdon J. Reply: Beyond the limits of detection: failure of PiB imaging to capture true Abeta burden. Movement Disorders, 28:407, 2013, PMC3741662.
4. Gomperts SN, Locascio JJ, Marquie M, Santarlasci AL, Rentz DM, Maye J, Johnson KA, Growdon JH. Brain amyloid and cognition in Lewy body diseases. Movement Disorders, 27:965-973, 2012, PMC3725259.
5. Growdon, J, Gomperts, S, Locascio, J, Rentz, D, Marquie Sayagues, M, Santarlasci, A and Johnson, K. Brain Amyloid and Cognition in PD. 10th Int'l Conference on Alzheimer's and Parkinson's Disease; Barcelona, Spain, 2011. (Abstract)

SAS Output

Co-Principal Investigator: Anne Fagan Niven & Alex Roher (NACC Project #2006-03,06)

Title: Proteomic Analysis of Post-mortem and Ante-mortem Cerebrospinal Fluid for the Diagnosis of Alzheimer’s Disease

Lead Institutions: WashU/Arizona ADC

6. Craig-Schapiro R, Perrin RJ, Roe CM, Grant EA, Carter D, Cairns NJ, Mintun MA, Peskind ER, Li G, Galasko DR, Clark CM, Quinn JF, D’Angelo G, Malone JP, Townsend R, Morris JC, Fagan AM, Holtzman DM. A Novel Diagnostic and Prognostic Fluid Biomarker for Early Alzheimer's Disease: YKL-40. Alzheimer's and Dementia, 6:S506, 2010. (Abstract)
7. Craig-Schapiro R, Perrin RJ, Roe CM, Xiong C, Carter D, Cairns NJ, Mintun MA, Peskind ER, Li G, Galasko DR, Clark CM, Quinn JF, D'Angelo G, Malone JP, Townsend RR, Morris JC, Fagan AM, Holtzman DM. YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease. Biol Psychiatry, 68:903-912, 2010, PMC3011944.
8. Maarouf, CL, Andacht, TM, Kokjohn, TA, Castano, EM, Sue, LI, Beach, TG and Roher, AE. Proteomic analysis of Alzheimer's disease cerebrospinal fluid from neuropathologically diagnosed subjects. Curr Alzheimer Res, 6:399-406, 2009, PMC2832860.
9. Perrin RJ, Craig-Schapiro R, Malone JP, Roe CM, Grant EA, Shah AR, Gilmore P, Davis AE, Peskind ER, Li G, Galasko DR, Quinn JF, Kaye JA, Clark CM, Morris JC, Holtzman DM, Townsend RR, Fagan AM. Identification and validation of novel cerebrospinal fluid protein biomarkers for early Alzheimer disease using proteomics and ELISA - a multi-institutional collaborative study. Alzheimer's and Dementia, 6:S500, 2010. (Abstract)
10. Perrin RJ, Craig-Schapiro R, Malone JP, Shah AR, Gilmore P, Davis AE, Roe CM, Peskind ER, Li G, Galasko DR, Clark CM, Quinn JF, Kaye JA, Morris JC, Holtzman DM, Townsend RR, Fagan AM. Identification and Validation of Novel Cerebrospinal Fluid Biomarkers for Staging Early Alzheimer's Disease. PLoS ONE, 6:e16032, 2011, PMC3020224.
11. Perrin RJ, Malone JP, Shah AR, Craig-Schapiro R, Gilmore P, Davis AE, Peskind ER, Ge L, Galasko DR, Quinn JF, Kaye JA, Clark CM, Morris JC, Holtzman DM, Townsend RR, Fagan AM. Identification of potential biomarkers for Alzheimer’s disease in cerebrospinal fluid using two-dimensional difference gel electrophoresis (2D-DIGE) and tandem mass spectrometry-a multi-institutional. Alzheimer's and Dementia, 4:T543, 2008. (Abstract)
12. Roher, AE, Maarouf, CL, Andacht, TM, Kokjohn, TA, Casta??o, EM, Walker, DG, Sabbagh, MN and Beach, TG. Proteomics-derived cerebrospinal fluid markers of autopsy-confirmed Alzheimer's disease. Alzheimer's and Dementia, 6:S123, 2010. (Abstract)
13. Roher, AE, Maarouf, CL, Sue, LI, Hu, Y, Wilson, J and Beach, TG. Proteomics-derived cerebrospinal fluid markers of autopsy-confirmed Alzheimer's disease. Biomarkers, 14:493-501, 2009, PMC2824250.

SAS Output

Principal Investigator: Mony J. deLeon (NACC Project #2006-09)

Title: Hippocampal Glucose Metabolism in Aging: Relationships to Cognitive Decline

Lead Institutions: New York University School of Medicine

14. Mosconi L, Tsui WH, Herholz K, Pupi A, Drzezga A, Lucignani G, Reiman EM, Holthoff V, Kalbe E, Sorbi S, Diehl-Schmid J, Perneczky R, Clerici F, Caselli R, Beuthien-Baumann B, Kurz A, Minoshima S, de Leon MJ. Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias. J Nucl Med, 49:390-398, 2008, PMC3703818.

SAS Output

Principal Investigator: Sandra Weintraub (NACC Project #2005-05)

Title: Clinical Phenotypes of FTD are Determined by Neuropathologic and Biochemical Features

Lead Institutions: Northwestern University

15. Armstrong, RA and Cairns, NJ. Analysis of beta-amyloid (Abeta) deposition in the temporal lobe in Alzheimer's disease using Fourier (spectral) analysis. Neuropathol Appl Neurobiol, 36:248-257, 2010, PMC2972722.
16. Armstrong, RA, Ellis, W, Hamilton, RL, Mackenzie, IR, Hedreen, J, Gearing, M, Montine, T, Vonsattel, JP, Head, E, Lieberman, AP and Cairns, NJ. Neuropathological heterogeneity in frontotemporal lobar degeneration with TDP-43 proteinopathy: a quantitative study of 94 cases using principal components analysis. J Neural Transm, 117:227-239, 2010, PMC2830004.
17. Cairns NJ, Bigio EH, Mackenzie IR, Neumann M, Lee VM, Hatanpaa KJ, White CL, 3rd, Schneider JA, Grinberg LT, Halliday G, Duyckaerts C, Lowe JS, Holm IE, Tolnay M, Okamoto K, Yokoo H, Murayama S, Woulfe J, Munoz DG, Dickson DW, Ince PG, Trojanowski JQ, Mann DM. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol, 114:22-May, 2007, PMC2827877.
18. Cairns NJ, Neumann M, Bigio EH, Holm IE, Troost D, Hatanpaa KJ, Foong C, White CL, 3rd, Schneider JA, Kretzschmar HA, Carter D, Taylor-Reinwald L, Paulsmeyer K, Strider J, Gitcho M, Goate AM, Morris JC, Mishra M, Kwong LK, Stieber A, Xu Y, Forman MS, Trojanowski JQ, Lee VM, Mackenzie IR. TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions. Am J Pathol, 171:227-240, 2007, PMC1941578.
19. Cairns, NJ, Pang-Hsien, T, Bigio, EH, Schneider, JA, White III, CL, Hatanpaa, K, Aggarwal, NT, Womake, KB, Schneider, S, Grinberg, LT, Morris, JC, Wicklund, AH and Weintraub, S. Neuropathologic heterogeneity in frontotemporal lobar degeneration (FTLD) with ubiquitin inclusions: Report of the Midwest consortium for FTLD. Brain Pathology, 16:S5, 2006. (Abstract)
20. Gitcho MA, Baloh RH, Chakraverty S, Mayo K, Norton JB, Levitch D, Hatanpaa KJ, White CL, 3rd, Bigio EH, Caselli R, Baker M, Al-Lozi MT, Morris JC, Pestronk A, Rademakers R, Goate AM, Cairns NJ. TDP-43 A315T mutation in familial motor neuron disease. Ann Neurol, 63:535-538, 2008, PMC2747362.
21. Gitcho MA, Bigio EH, Mishra M, Johnson N, Weintraub S, Mesulam M, Rademakers R, Chakraverty S, Cruchaga C, Morris JC, Goate AM, Cairns NJ. TARDBP 3'-UTR variant in autopsy-confirmed frontotemporal lobar degeneration with TDP-43 proteinopathy. Acta Neuropathol, 118:633-645, 2009, PMC2783457.
22. Hatanpaa, KJ, Bigio, EH, Cairns, NJ, Schneider, JA, Foong, C, Hladik, C, Shang, P and White, CL. TDP-43 immunohistochemistry reveals extensive neuritic pathology in FTLD-U: a Midwest-Southwest Consortium for FTLD study. J Neuropathol Exp Neurol, 66:425, 2007. (Abstract)
23. Hatanpaa, KJ, Bigio, EH, Cairns, NJ, Womack, KB, Weintraub, S, Morris, JC, Foong, C, Xiao, G, Hladik, C, Mantanona, TY and White, CL, 3rd. TAR DNA-binding protein 43 immunohistochemistry reveals extensive neuritic pathology in FTLD-U: a midwest-southwest consortium for FTLD study. J Neuropathol Exp Neurol, 67:271-279, 2008, PMC2635119.
24. Liscic, RM, Grinberg, LT, Zidar, J, Gitcho, MA and Cairns, NJ. ALS and FTLD: two faces of TDP-43 proteinopathy. Eur J Neurol, 15:772-780, 2008, PMC2801606.

SAS Output

Principal Investigator: Debby Tsuang, MD (NACC Project #2003-03)

Title: Clinical, Pathologic, and Genetic Characteristics of Dementia with Lewy Bodies

Lead Institutions: University of Washington

25. Bekris LM, Tsuang D, Leverenz JB, Yu CE, Lutz F, Lopez OL, Hamilton RL, Bennett DA, Schneider JA, Buchman AS, Larson EB, Crane PK, Kaye JA, Kramer P, Woltjer R, Trojanowski JQ, Weintraub D, Chen-Plotkin AS, Irwin DJ, Rick J, Schellenberg GD, Watson GS, Kukull W, Nelson PT, Jicha GA, Neltner JH, Galasko D, Masliah E, Quinn JF, Chung KA, Yearout D, Mata IF, Edwards KL, Montine TJ, Zabetian CP. A TOMM40 SNP in APOE ?4 Non-carriers Increases Risk for Multiple Types of Dementia. Alzheimers and Dementia, 9:P555, 2013. (Abstract)
26. Chow, SW, Peterson, M, Vavrek, DJ, Steinbart, E, Bird, TD, Leverenz, JB and Tsuang, DW. Diagnostic Accuracy of Concomitant Lewy-Related Pathology in a Kindred with Familial Alzheimer's Disease: a Clinical-Neuropathological Study. Summer Training on Aging Research Topics in Mental Health (START-MH), 2006. (Abstract)
27. Ericksen S, Tsuang DW. Dementia with Lewy bodies. In: Fuji D, Ahmed I, eds Spectrum Psychotic Disorders: Neurobiology, Etiology & Pathogenesis New York: Cambridge University Press, 472-489, 2007.
28. Leverenz JB, Hamilton R, Tsuang DW, Schantz A, Vavrek D, Larson EB, Kukull WA, Lopez O, Galasko D, Masliah E, Kaye J, Woltjer R, Clark C, Trojanowski JQ, Montine TJ. Empiric refinement of the pathologic assessment of Lewy-related pathology in the dementia patient. Brain Pathol, 18:220-224, 2008, PMC2689097.
29. Leverenz JB, Hamilton RL, Tsuang DW, Schantz A, Vavrek D, Larson EB, Kukull WA, Lopez OL, Galasko D, Masliah E, Kaye J, Nixon R, Clark C, Trojanowski J, Montine TJ. Empirical refinement of pathologic assessment of Dementia with Lewy Bodies. Alzheimer’s and Dementia, 2006. (Abstract)
30. Leverenz, JB, Fishel, MA, Peskind, ER, Montine, TJ, Nochlin, D, Steinbart, E, Raskind, MA, Schellenberg, GD, Bird, TD and Tsuang, D. Lewy body pathology in familial Alzheimer disease - Evidence for disease- and mutation-specific pathologic phenotype. Arch Neurol, 63:370-376, 2006, PMC1892620.
31. Leverenz, JB, Larson, EB, Vavrek, D, Peskind, ER, Bowen, JD, McCormick, WC, Teri, L, Kukull, WA, Montine, TJ and Tsuang, DW. "Amygdala predominant" Lewy body disease: a subtype of Alzheimer's disease with a more aggressive clinical course. Alzheimer’s and Dementia, 2:S16, 2006. (Abstract)
32. Lopez, A, Samii, A, Griffith, A, Roberts, J, Leis, B, Mosley, A, Yearout, D, Schellenberg, G, Bird, T, Raskind, W, Leverenz, J, Tsuang, D and Zabetian, C. Comprehensive mutational analysis of LRRK2 in familial Parkinson's disease and dementia with Lewy bodies. Neurology, 66:277, 2006. (Abstract)
33. Mata, IF, Samii, A, Schneer, SH, Roberts, JW, Griffith, A, Leis, BC, Schellenberg, GD, Sidransky, E, Bird, TD, Leverenz, JB, Tsuang, D and Zabetian, CP. Glucocerebrosidase gene mutations: a risk factor for lewy body disorders. Arch Neurol, 65:379-382, 2008, PMC2826203.
34. Mata, IF, Schneer, SH, Samii, A, Roberts, JW, Griffith, AF, Leis, BC, Leverenz, JB, Schellenberg, GD, Sidransky, E, Tsuang, DW and Zabetian, CP. Case-control analysis of glucocerebrosidase gene mutations in Parkinson's disease and dementia with Lewy bodies. Movement Disorders, 22:S128-S129, 2007. (Abstract)
35. Nakashima-Yasuda H, Uryu K, Robinson J, Xie SX, Hurtig H, Duda JE, Arnold SE, Siderowf A, Grossman M, Leverenz JB, Woltjer R, Lopez OL, Hamilton R, Tsuang DW, Galasko D, Masliah E, Kaye J, Clark CM, Montine TJ, Lee VM, Trojanowski JQ. Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathol, 114:221-229, 2007.
36. Ohtake H, Limprasert P, Fan Y, Onodera O, Kakita A, Takahashi H, Bonner LT, Tsuang DW, Murray IV, Lee VM, Trojanowski JQ, Ishikawa A, Idezuka J, Murata M, Toda T, Bird TD, Leverenz JB, Tsuji S, La Spada AR. Beta-synuclein gene alterations in dementia with Lewy bodies. Neurology, 63:805-811, 2004, PMC1808539.
37. Schneer, S, Mata, IF, Samii, A, Roberts, JW, Griffith, A, Leis, BC, Leverenz, JB, Schellenberg, GD, Sidransky, E, Tsuang, DW and Zabetian, CP. Case-control Analysis of Glucocerebrosidase Gene Mutations in Parkinson's Disease and Dementia with Lewy Bodies. American Academy of Neurology, 2007. (Abstract)
38. Tsuang D, Leverenz JB, Lopez OL, Hamilton RL, Bennett DA, Schneider JA, Buchman AS, Larson EB, Crane PK, Kaye JA, Kramer P, Woltjer R, Kukull W, Nelson PT, Jicha GA, Neltner JH, Galasko D, Masliah E, Trojanowski JQ, Schellenberg GD, Yearout D, Huston H, Fritts-Penniman A, Mata IF, Wan JY, Edwards KL, Montine TJ, Zabetian CP. GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology. Neurology, 79:1944-1950, 2012, PMC3484986.
39. Tsuang, D, Larson, EB, Bolen, E, Thompson, ML, Peskind, E, Bowen, J, McCormick, W, Teri, L, Kukull, W, Vavrek, D, Montine, T and Leverenz, JB. Visual hallucinations in dementia: a prospective community-based study with autopsy. Am J Geriatr Psychiatry, 17:317-323, 2009, PMC2742470.
40. Tsuang, D, Simpson, K, Larson, EB, Peskind, E, Kukull, W, Bowen, JB, McCormick, W, Teri, L, Montine, T, Thompson, ML and Leverenz, JB. Predicting lewy body pathology in a community-based sample with clinical diagnosis of Alzheimer's disease. J Geriatr Psychiatry Neurol, 19:195-201, 2006.
41. Tsuang, DW, Hamilton, RL, Lopez, OL, Wilson, R, Luedecking-Zimmer, E, Kamboh, L, DeKosky, ST, Larson, EB, Kukull, WA, Schellenberg, GD and Leverenz, J. Age and concomitant LB pathology modify the genetic association between Alzheimer's disease and the APOE-e4 allele. 3rd International Workshop on Dementia with Lewy Bodies and Parkinson’s Disease; Dementia Conference Handbook, 147, 2003. (Abstract)
42. Tsuang, DW, Larson, EB, Peskind, ER, Bowen, JB, McCormick, W, Teri, L, Jennings-Vavrek, D, Montine, T, Thompson, ML and Leverenz, JB. Visual hallucinations and Lewy body pathology: a community-based autopsy case series. Alzheimer’s and Dementia, 2:S146, 2006. (Abstract)
43. Tsuang, DW, Purganan, K, Steinbart, E, Bird, TD, Montine, T and Leverenz, JB. Concomitant Lewy body pathology a marker for more aggressive course in familial Alzheimer's disease. Neurology, 64:A361-A362, 2005. (Abstract)
44. Tsuang, DW, Riekse, R, Bird, TD, Muilenberg, M, Steinbart, E, McCutcheon, M, Purganan, K and Leverenz, JB. Familial Dementia with Lewy Bodies. Neurobiol Aging, 25:86, 2004. (Abstract)
45. Tsuang, DW, Riekse, RG, Purganan, KM, David, AC, Montine, TJ, Schellenberg, GD, Steinbart, EJ, Petrie, EC, Bird, TD and Leverenz, JB. Lewy body pathology in late-onset familial Alzheimer's disease: A clinicopathological case series. J Alzheimers Dis, 9:235-242, 2006.
46. Tsuang, DW, Wilson, RK, Lopez, OL, Luedecking-Zimmer, EK, Leverenz, JB, DeKosky, ST, Kamboh, MI and Hamilton, RL. Genetic association between the APOE*4 allele and Lewy bodies in Alzheimer disease. Neurology, 64:509-513, 2005, PMC1487185.
47. Zabetian, CP, Lauricella, CJ, Tsuang, DW, Leverenz, JB, Schellenberg, GD and Payami, H. Analysis of the LRRK2 G2019S mutation in Alzheimer Disease. Arch Neurol, 63:156-157, 2006.

SAS Output

Principal Investigator: Roger Rosenberg, MD (NACC Project #2002-01)

Title: Statin Effects on Platelet APP Ratios and AD Dementia

Lead Institutions: University of Texas Southwestern

48. Baskin, F, Rosenberg, RN, Fang, X, Hynan, LS, Moore, CB, Weiner, M and Vega, GL. Correlation of platelet amyloid precursor protein ratios and declining cognition in Alzheimer's disease: A new severity index. Neurobiol Aging, 23:S384, 2002. (Abstract)
49. Baskin, F, Rosenberg, RN, Fang, X, Hynan, LS, Moore, CB, Weiner, M and Vega, GL. Correlation of statin-increased platelet APP ratios and reduced blood lipids in AD patients. Neurology, 60:2006-2007, 2003.
50. Diaz-Arrastia, R and Baskin, F. New biochemical markers in Alzheimer disease. Arch Neurol, 58:354-356, 2001.
51. Qu, B, Boyer, PJ, Johnston, SA, Hynan, LS and Rosenberg, RN. Abeta42 gene vaccination reduces brain amyloid plaque burden in transgenic mice. J Neurol Sci, 244:151-158, 2006, PMC1531642.
52. Qu, B, Rosenberg, RN, Li, L, Boyer, PJ and Johnston, SA. Gene vaccination to bias the immune response to amyloid-beta peptide as therapy for Alzheimer disease. Arch Neurol, 61:1859-1864, 2004.
53. Qu, BX, Xiang, Q, Li, L, Johnston, SA, Hynan, LS and Rosenberg, RN. Abeta42 gene vaccine prevents Abeta42 deposition in brain of double transgenic mice. J Neurol Sci, 260:204-213, 2007, PMC2587214.
54. Tang, K, Hynan, LS, Baskin, F and Rosenberg, RN. Platelet amyloid precursor protein processing: a bio-marker for Alzheimer's disease. J Neurol Sci, 240:53-58, 2006, PMC1479090.

SAS Output

Principal Investigator: Harry Vinters (NACC Project #2002-03)

Title: Tissue Reactions to CAA Study Using Tissue Microarrays (CNS Complications of Amyloid Angiopathy)

Lead Institutions: University of California, Los Angeles

55. Farag, ES, Miyata, H and Vinters, HV. CAA severity and reactive change in Alzheimer disease: A tissue microarray study. J Neuropathol Exper Neurol, 62:553, 2003. (Abstract)
56. Green, DA, Masliah, E, Vinters, HV, Beizai, P, Moore, DJ and Achim, CL. Brain deposition of beta-amyloid is a common pathologic feature in HIV positive patients. Aids, 19:407-411, 2005.
57. Vinters, HV, Klement, IA, Sung, SH and Farag, ES. Pathologic issues and new methodologies in the evaluation of non-Alzheimer dementias. Clin Neuroscience Res, 3:413-426, 2004.

SAS Output

Principal Investigator: Robert Sweet, MD (NACC Project #2002-04)

Title: Genetics of Alzheimer’s Disease With Psychosis

Lead Institutions: University of Pittsburgh

58. Bacanu, SA, Devlin, B, Chowdari, KV, DeKosky, ST, Nimgaonkar, VL and Sweet, RA. Heritability of psychosis in Alzheimer disease. Am J Geriatric Psychiatry, 13:624-627, 2005.
59. Cook, SE, Miyahara, S, Bacanu, SA, Perez-Madrinan, G, Lopez, OL, Kaufer, DI, Nimgaonkar, VL, Wisniewski, SR, DeKosky, ST and Sweet, RA. Psychotic symptoms in Alzheimer disease: evidence for subtypes. Am J Geriatr Psychiatry, 11:406-413, 2003.
60. Eror, EA, Emanuel, JE, Miyahara, S, Lopez, OL, DeKosky, ST and Sweet, RA. Excess Cognitive Impairment Precedes The Emergence Of Psychosis In Alzheimer Disease. Alzheimer’s and Dementia, 2:S375-376, 2006. (Abstract)
61. Eror, EA, Lopez, OL, DeKosky, ST and Sweet, RA. AD subjects with psychosis have increased subsyndromal psychotic symptoms prior to dementia onset. Neurobiol Aging, 25:S489, 2004. (Abstract)
62. Eror, EA, Lopez, OL, Dekosky, ST and Sweet, RA. Alzheimer disease subjects with psychosis have increased schizotypal symptoms before dementia onset. Biol Psychiatry, 58:325-330, 2005.
63. Go, RC, Perry, RT, Wiener, H, Bassett, SS, Blacker, D, Devlin, B and Sweet, RA. Neuregulin-1 polymorphism in late onset Alzheimer's disease families with psychoses. Am J Med Genet Neuropsychiatr Genet, 139:28-32, 2005.
64. Go, RC, Perry, RT, Wiener, H, Bassett, SS, Blacker, D, Devlin, BJ and Sweet, RA. Neuregulin-1 polymorphism in load with psychosis in the NIMH AD sibling families. Neurobiol Aging, 25:S488, 2004. (Abstract)
65. Lopez OL, Miyahara S, Becker JT, Sweet RA, Klunk W, Saxton J, DeKosky ST. Incident psychiatric symptoms predict conversion to dementia in Mild Cognitive Impairment subgroups. In: Vellas B, ed Research and Practice in Alzheimer's Disease and Cognitive Decline: Paris, Serdi, 89-95, 2005.
66. Lopez, OL, Becker, JT and Sweet, RA. Non-cognitive symptoms in mild cognitive impairment subjects. Neurocase, 11:65-71, 2005.
67. Lopez, OL, Becker, JT, Saxton, J, Sweet, RA, Klunk, W and DeKosky, ST. Alteration of a clinically meaningful outcome in the natural history of Alzheimer's disease by cholinesterase inhibition. J Am Geriatr Soc, 53:83-87, 2005.
68. Lopez, OL, Becker, JT, Sweet, RA, Hamilton, RL and DeKosky, ST. Relationship between major depression and Lewy bodies in Alzheimer's disease. Neurology, 62:A159-A160, 2004. (Abstract)
69. Lopez, OL, Becker, JT, Sweet, RA, Klunk, W, Kaufer, DI, Saxton, J and DeKosky, ST. Patterns of change in the treatment of psychiatric symptoms in patients with probable Alzheimer's disease from 1983 to 2000. J Neuropsychiatry Clin Neurosci, 15:67-73, 2003.
70. Lopez, OL, Becker, JT, Sweet, RA, Klunk, W, Kaufer, DI, Saxton, J, Habeych, M and DeKosky, ST. Psychiatric symptoms vary with the severity of dementia in probable Alzheimer's disease. J Neuropsychiatry Clin Neurosci, 15:346-353, 2003.
71. Lopez, OL, Becker, JT, Sweet, RA, Klunk, W, Saxton, J and DeKosky, ST. Incident psychiatric symptoms predict conversion to dementia in mild cognitive impairment subgroups. Neurobiol Aging, 25:S32, 2004. (Abstract)
72. Lopez, OL, Becker, JT, Sweet, RS, Klunk, W, Saxton, J and DeKosky, ST. Response letter to Dr Thomas Finucane. J Am Geriatr Soc, 53:1831-1833, 2005.
73. Lopez, OL. Incident Psychiatric symptoms predict the development of Mild Cognitive Impairment subgroups. Ninth International Conference on Alzheimer Disease and Related Disorders, 2004. (Presentation)
74. Perez-Madrinan, G, Cook, SE, Saxton, JA, Miyahara, S, Lopez, OL, Kaufer, DI, Aizenstein, HJ, DeKosky, ST and Sweet, RA. Alzheimer disease with psychosis: excess cognitive impairment is restricted to the misidentification subtype. J Geriatr Psychiatry, 12:449-456, 2004.
75. Perez-Madrinan, G, Cook, SE, Saxton, JA, Miyahara, S, Lopez, OL, Kaufer, DI, Aizenstein, HJ, DeKosky, ST and Sweet, RA. Psychosis in Alzheimer Disease: Excess Cognitive Impairment is Restricted to the Misidentification Subtype. Advances in Geriatric Psychiatry Translating Research Into Care:101, 2003. (Abstract)
76. Prasad, KMR, Davis, SW, Becker, JT, Keshavan, MS and Sweet, RA. Neurobiological substrates of Alzheimer Disease with psychosis: an exploratory study of structural MRI using a voxel-based morphometric approach. Society for Neuroscience 33rd Annual Meeting, 2003. (Abstract)
77. Sweet R, Emanuel J E. Psychosis Secondary to Alzheimer Disease. In: Ahmed DFaI, ed The Spectrum of Psychotic Disorders: Neurobiology, Etiology, and Pathogenesis Cambridge UK: Cambridge University Press, 2005.
78. Sweet, RA, Bacanu, SA, Devlin, B, Chowdari, KV, DeKosky, ST and Nimgaonkar, VL. Heritability of psychosis in Alzheimer disease. Neurobiol Aging, 25:S54, 2004. (Abstract)
79. Sweet, RA, Devlin, B, Pollock, BG, Sukonick, DL, Kastango, KB, Bacanu, SA, Chowdari, KV, DeKosky, ST and Ferrell, RE. Catechol-o-methyltransferase haplotype is associated with psychosis in Alzheimer's disease. American Association for Geriatric Psychiatry 17th Annual Meeting, Baltimore MD, 2004. (Abstract)
80. Sweet, RA, Devlin, B, Pollock, BG, Sukonick, DL, Kastango, KB, Bacanu, SA, Kodavali, VC, DeKosky, ST and Ferrell, RE. Catechol-o-methyltransferase haplotype is associated with psychosis in Alzheimer's disease. Molecular Psych, 10:1026-1036, 2005.
81. Sweet, RA. Genetics of Alzheimer Disease with Psychosis. SOBP Annual Convention and Scientific Program San Francisco California, 2003. (Presentation)
82. Sweet, RA. Heritability of Psychosis in Alzheimer Disease. Ninth International Conference on Alzheimer Disease and Related Disorders, 2004. (Abstract)
83. Sweet, RA. Recent Advances in the Clinical Neuroscience of Alzheimer's Disease. American Association for Geriatric Psychiatry 17th Annual Meeting, 2004. (Presentation)
84. Sweet, RA. Spanning the GAP: Genes, Alzheimer Disease, and Psychosis. Grand Rounds Mt Sinai School of Medicine, 2005. (Presentation)
85. Sweet, RA. Taking a New Look At Psychosis in Alzheimer's Disease. GRECC Weekly Conference Series, VA Hospital , Pittsburgh PA, 2003. (Presentation)
86. Sweet, RA. The genetic basis of psychosis in Alzheimer Disease (and why it matters). Geriatric Research, Education and Clinical Center (CRECC) conference series, 2006. (Presentation)
87. Wilkosz, PA, Miyahara, S, Lopez, O, Dekosky, S and Sweet, R. Psychotic symptoms identify subtypes of AD: A prospective validation study. Neurobiol Aging, 25:S495, 2004. (Abstract)
88. Wilkosz, PA, Miyahara, S, Lopez, OL, DeKosky, ST and Sweet, RA. HTR2A Genotype, Depression, And Risk For Psychosis Onset In Alzheimer Disease. Precedings of the International Congress on Geriatric Psychoneuropharmacology, 2005. (Abstract)
89. Wilkosz, PA, Miyahara, S, Lopez, OL, DeKosky, ST, Eror, EA and Sweet, RA. HTR2A genotype, depression, and risk for psychosis onset in Alzheimer disease. Alzheimer's and Dementia, 2:S183, 2006. (Abstract)
90. Wilkosz, PA, Miyahara, S, Lopez, OL, Dekosky, ST and Sweet, RA. Prediction of psychosis onset in Alzheimer disease: The role of cognitive impairment, depressive symptoms, and further evidence for psychosis subtypes. Am J Geriatr Psychiatry, 14:352-360, 2006.

SAS Output

Principal Investigator: John Morris, MD (NACC Project #2001-03)

Title: Neuropathologic Correlates of Nondemented Aging

Lead Institutions: Washington University

91. Burack, MA, Hartlein, J, Flores, HP, Taylor-Reinwald, L, Perlmutter, JS and Cairns, NJ. In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia. Neurology, 74:77-84, 2010, PMC2809026.
92. Morris J. Neuropathologic Correlates of Non-demented Aging. In Washington University, 2001.
93. Morris, JC, Price, JL, McKeel Jr, DW, Higdon, R and Buckles, VD. The Neuropathology of Nondemented Aging. Neurobiol Aging, 25:137, 2004. (Abstract)
94. Price JL, McKeel DW, Jr, Buckles VD, Roe CM, Xiong C, Grundman M, Hansen LA, Petersen RC, Parisi JE, Dickson DW, Smith CD, Davis DG, Schmitt FA, Markesbery WR, Kaye J, Kurlan R, Hulette C, Kurland BF, Higdon R, Kukull W, Morris JC. Neuropathology of nondemented aging: Presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging, 30:1026-1036, 2009, PMC2737680.

SAS Output

Principal Investigator: Elaine Peskind, MD (NACC Project #2001-04)

Title: CSF Cortisol and APOE Genotype

Lead Institutions: University of Washington

95. Abdi F, Quinn JF, Jankovic J, McIntosh M, Leverenz JB, Peskind E, Nixon R, Nutt J, Chung K, Zabetian C, Samii A, Lin M, Hattan S, Pan C, Wang Y, Jin J, Zhu D, Li GJ, Liu Y, Waichunas D, Montine TJ, Zhang J. Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis, 9:293-348, 2006.
96. Friedman, LF, Zeitzer, JM, Lin, L, Hoff, D, Mignot, E, Peskind, ER and Yesavage, JA. In Alzheimer disease, increased wake fragmentation found in those with lower hypocretin-1. Neurology, 68:793-794, 2007.
97. Li, G, Sokal, I, Quinn, JF, Leverenz, JB, Brodey, M, Schellenberg, GD, Kaye, JA, Raskind, MA, Zhang, J, Peskind, ER and Montine, TJ. CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology, 69:631-639, 2007.
98. Pan, S, Wang, Y, Quinn, JF, Peskind, ER, Waichunas, D, Wimberger, JT, Jin, J, Li, JG, Zhu, D, Pan, C and Zhang, J. Identification of glycoproteins in human cerebrospinal fluid with a complementary proteomic approach. J Proteome Res, 5:2769-2779, 2006.
99. Pan, S, Zhu, D, Quinn, JF, Peskind, ER, Montine, TJ, Lin, B, Goodlett, DR, Taylor, G, Eng, J and Zhang, J. A combined dataset of human cerebrospinal fluid proteins identified by multi-dimensional chromatography and tandem mass spectrometry. Proteomics, 7:469-473, 2007.
100. Pasinetti, GM, Ungar, LH, Lange, DJ, Yemul, S, Deng, H, Yuan, X, Brown, RH, Cudkowicz, ME, Newhall, K, Peskind, E, Marcus, S and Ho, L. Identification of potential CSF biomarkers in ALS. Neurology, 66:1218-1222, 2006.
101. Peskind, ER, Griffin, WS, Akama, KT, Raskind, MA and Van Eldik, LJ. Cerebrospinal fluid S100B is elevated in the earlier stages of Alzheimer's disease. Neurochem Int, 39:409-413, 2001.
102. Peskind, ER, Li, G, Shofer, J, Quinn, JF, Kaye, JA, Clark, CM, Farlow, MR, DeCarli, C, Raskind, MA, Schellenberg, GD, Lee, VM and Galasko, DR. Age and apolipoprotein E*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition. Arch Neurol, 63:936-939, 2006.
103. Peskind, ER, Wilkinson, CW, Petrie, EC, Schellenberg, GD and Raskind, MA. Increased CSF cortisol in AD is a function of APOE genotype. Neurology, 56:1094-1098, 2001.
104. Riekse RG, Li G, Petrie EC, Leverenz JB, Vavrek D, Vuletic S, Albers JJ, Montine TJ, Lee VM, Lee M, Seubert P, Galasko D, Schellenberg GD, Hazzard WR, Peskind ER. Effect of statins on Alzheimer's disease biomarkers in cerebrospinal fluid. J Alzheimers Dis, 10:399-406, 2006.
105. Vuletic, S, Peskind, ER, Marcovina, SM, Quinn, JF, Cheung, MC, Kennedy, H, Kaye, JA, Jin, LW and Albers, JJ. Reduced CSF PLTP activity in Alzheimer's disease and other neurologic diseases; PLTP induces ApoE secretion in primary human astrocytes in vitro. J Neurosci Res, 80:406-413, 2005.
106. Vuletic, S, Riekse, RG, Marcovina, SM, Peskind, ER, Hazzard, WR and Albers, JJ. Statins of different brain penetrability differentially affect CSF PLTP activity. Dement Geriatr Cogn Disord, 22:392-398, 2006.
107. Xu, J, Chen, J, Peskind, ER, Jin, J, Eng, J, Pan, C, Montine, TJ, Goodlett, DR and Zhang, J. Characterization of proteome of human cerebrospinal fluid. Int Rev Neurobiol, 73:29-98, 2006.
108. Zhang H, Loriaux P, Eng J, Campbell D, Keller A, Moss P, Bonneau R, Zhang N, Zhou Y, Wollscheid B, Cooke K, Yi EC, Lee H, Peskind ER, Zhang J, Smith RD, Aebersold R. UniPep--a database for human N-linked glycosites: a resource for biomarker discovery. Genome Biol, 7:R73, 2006, PMC1779586.
109. Zhang, J, Goodlett, DR, Peskind, ER, Quinn, JF, Zhou, Y, Wang, Q, Pan, C, Yi, E, Eng, J, Aebersold, RH and Montine, TJ. Quantitative proteomic analysis of age-related changes in human cerebrospinal fluid. Neurobiol Aging, 26:207-227, 2005.
110. Zhang, J, Goodlett, DR, Quinn, JF, Peskind, E, Kaye, JA, Zhou, Y, Pan, C, Yi, E, Eng, J, Wang, Q, Aebersold, RH and Montine, TJ. Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease. J Alzheimers Dis, 7:125-133, 2005.

SAS Output

Principal Investigator: Norman Foster (NACC Project #2000-04)

Title: Collaborative PET Imaging Study

Lead Institutions: University of Michigan

111. Foster NL, Koeppe RE, Giordani BJ, Nichols TE, Lieberman AP. Variations of the phenotype in frontotemporal dementias. In: Cummings J, Hardy J, Poncet M, Christen Y, eds Genotype - Proteotype - Phenotype Relationships in Neurodegenerative Diseases Berlin: Spinger-Verla, 139-152, 2005.
112. Foster, NL, Barbas, NR, Heidebrink, JL, Turner, RS, Clark, CM, Jagust, WJ, Arnold, SE, DeCarli, CS, Koeppe, RA and Higdon, R. Adding FDG-PET to clinical information improves the accuracy of dementia diagnosis. Neurobiol Aging, 25:372, 2004. (Abstract)
113. Foster, NL, Heidebrink, JL, Clark, CM, Jagust, WJ, Arnold, SE, Barbas, NR, DeCarli, C, Turner, RS, Koeppe, RA, Higdon, R and S, M. Inter-rater reliability and diagnostic accuracy of FDG-PET is superior to clinical history and examination in dementia. Neurobiol Aging, 23:S353, 2002. (Abstract)
114. Foster, NL, Heidebrink, JL, Clark, CM, Jagust, WJ, Arnold, SE, Barbas, NR, DeCarli, CS, Turner, RS, Koeppe, RA, Higdon, R and Minoshima, S. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. Brain, 130:2616-2635, 2007.
115. Foster, NL, Koeppe, RA, Rogers, V, Minoshima, S, Clark, CM, Jagust, WJ, Arnold, SE, Barbas, NR, DeCarli, CS, Heidebrink, JL, Turner, RS and R, H. A multi-center trial to evaluate the clinical utility of FDG-PET. 2nd meeting of the Alzheimer’s Imaging Consortium, 2002. (Abstract)
116. Foster, NL, Poynter, JA, Heidebrink, JL, Jagust, WJ, Clark, CM, Turn, RS, Barbas, NR, Arnold, SE, DeCarli, C, Koeppe, RA, Higdon, R and Minoshima, S. Good diagnostic inter-rater reliability in a multicenter study of FDG-PET in the evaluation of dementia. Neurology, 58:S3, 2002. (Abstract)
117. Foster, NL. FDG PET in the Diagnosis of Frontotemporal Dementia. Biol Psychiatry, 57:45, 2005. (Abstract)
118. Foster, NL. Validating FDG-PET as a biomarker for frontotemporal dementia. Exper Neurol, 184:S2-8, 2003.
119. Gabel MJ, Foster NL, Heidebrink JL, Higdon R, Aizenstein HJ, Arnold SE, Barbas NR, Boeve BF, Burke JR, Clark CM, Dekosky ST, Farlow MR, Jagust WJ, Kawas CH, Koeppe RA, Leverenz JB, Lipton AM, Peskind ER, Turner RS, Womack KB, Zamrini EY. Validation of consensus panel diagnosis in dementia. Arch Neurol, 67:1506-1512, 2010, PMC3178413.
120. Heidebrink, JL, Barbas, NR, Turner, RS, Clark, CM, Jagust, WJ, Arnold, SE, DeCarli, CS, Koeppe, RA, Higdon, R and Foster, NL. FDG-PET improves differential diagnosis of dementia when clinical history and examination are ambiguous. Neurobiol Aging, 25:370, 2004. (Abstract)
121. Higdon, R, Foster, NL, Koeppe, RA, DeCarli, CS, Jagust, WJ, Clark, CM, Barbas, NR, Arnold, SE, Turner, RS, Heidebrink, JL and Minoshima, S. A comparison of classification methods for differentiating fronto-temporal dementia from Alzheimer's disease using FDG-PET imaging. Stat Med, 23:315-326, 2004.
122. Womack, KB, Diaz-Arrastia, R, Aizenstein, HJ, Arnold, SE, Barbas, NR, Boeve, BF, Clark, CM, DeCarli, CS, Jagust, WJ, Leverenz, JB, Peskind, ER, Turner, S, Zamrini, EY, Heidebrink, JL, Burke, JR, DeKosky, ST, Farlow, MR, Gabel, MJ, Higdon, R, Kawas, CH, Koeppe, RA, Lipton, AM, Foster, NL. Temporoparietal Hypometabolism in Frontotemporal Lobar Degeneration and Associated Imaging Diagnostic Errors. Arch Neurol, 68:329-337, 2011, PMC3058918.

SAS Output

Principal Investigator: Douglas Galasko, MD (NACC Project #2000-05)

Title: Clinico-pathologic Studies in Fronto-Temporal Dementia

Lead Institutions: University of California, San Diego

123. Rascovsky, K, Salmon, D, Clark, C, DeCarli, C, Graff-Radford, N, Leverenz, J and Galasko, D. Rate of progression differs in frontotemporal dementia and Alzheimer's disease. Neurology, 62:A344, 2004. (Abstract)
124. Rascovsky, K, Salmon, DP, Lipton, AM, Leverenz, JB, DeCarli, C, Jagust, WJ, Clark, CM, Mendez, MF, Tang-Wai, DF, Graff-Radford, NR and Galasko, D. Rate of progression differs in frontotemporal dementia and Alzheimer disease. Neurology, 65:397-403, 2005.

SAS Output

Principal Investigator: John Growdon, MD (NACC Project #2000-06)

Title: Consortium on Alzheimer’s Genetics

Lead Institutions: Massachusetts ADRC

125. Bertram L, Hiltunen M, Parkinson M, Ingelsson M, Lange C, Ramasamy K, Mullin K, Menon R, Sampson AJ, Hsiao MY, Elliott KJ, Velicelebi G, Moscarillo T, Hyman BT, Wagner SL, Becker KD, Blacker D, Tanzi RE. Family-based association between Alzheimer's disease and variants in UBQLN1. N Engl J Med, 352:884-894, 2005.
126. Bertram, L and Tanzi, RE. Author reply: The Ubiquitin 1 gene and Alzheimer's disease. N Engl J Med, 352:26, 2005.
127. Bertram, L, Hsiao, M, Mullin, K, Parkinson, M, Menon, R, Moscarillo, TJ, Blacker, D and Tanzi, RE. ACAT1 is not associated with Alzheimer's disease in two independent family-based samples. Mol Psychiatry, 10:522-524, 2005.
128. Bertram, L, Parkinson, M, McQueen, MB, Mullin, K, Hsiao, M, Menon, R, Moscarillo, TJ, Blacker, D and Tanzi, RE. Further evidence for LBP-1c/CP2/LSF association in Alzheimer's disease families. J Med Genet, 42:857-862, 2005.
129. Mullin, K, Bertram, L, Moscarillo, T, Becker, KD, Wang, C, Growdon, J, Blacker, D, Tanzi, RE and Group, tCAGS. Genetic association within the IDE region on chromosome 10-the consortium on Alzheimer's genetics (CAG). 33rd annual meeting of the Society for Neuroscience, 2003. (Abstract)

SAS Output

Principal Investigator: Michael Grundman, MD PhD (NACC Project #3)

Title: A Multi-Center Collaboration to Evaluate Candidate Agents for AD Prevention Trials

Lead Institutions: University of California, San Diego

130. Grundman M. The Alzheimer’s Disease Centers’ Neuropsychological Database Initiative: A Resource for Alzheimer’s Disease Prevention Trials. In: Alzheimer’s Disease: Advances in Etiology, Pathogenesis and Therapeutics New York: Wiley, 2001.
131. Grundman, M. Antioxidant Supplements are Associated with a Lower Risk of Developing Mild Cognitive Impairment or Alzheimer's Disease among Healthy Elderly Volunteers. Neuroscience, 546:516, 2001. (Abstract)
132. Ji, M, Xiong, C and Grundman, M. Hypothesis testing of a change point during cognitive decline among Alzheimer's disease patients. J Alzheimers Dis, 5:375-382, 2003.

SAS Output

Principal Investigator: Neil Kowall, MD (NACC Project #5)

Title: Collaborative Study Group on Vascular Pathology

Lead Institutions: Boston University

133. McKee, A, Au, R, Cabral, H, Auerbach, S, Green, R, Kowall, N and Wolf, P. Microvascular lesions distinguish cognitively impaired subjects without Alzheimer's disease from unimpaired subjects: Findings from the Framingham Heart Study. Vas Cog, 2005. (Abstract)
134. Yip, AG, McKee, A, Wells, J, Green, RC, Young, H, Cupples, LA and Farrer, LA. APOE, vascular pathology, and the AD brain. Neurobiol Aging, 25:403, 2004. (Abstract)
135. Yip, AG, McKee, AC, Green, RC, Wells, J, Young, H, Cupples, LA and Farrer, LA. APOE, vascular pathology, and the AD brain. Neurology, 65:2259-265, 2005.

SAS Output

Principal Investigator: Bernardino Ghetti (NACC Project #8)

Title: Identification of Atypical Dementias from Neuropathology to Molecular Etiology

Lead Institutions: Indiana University

136. Adamec, E, Murrell, JR, Takao, M, Hobbs, W, Nixon, RA, Ghetti, B and Vonsattel, JP. P301L tauopathy: confocal immunofluorescence study of perinuclear aggregation of the mutated protein. J Neurol Sci, 200:85-93, 2002.
137. Azzarelli, B, Miravalle, L, Olson, J, Ghetti, B, Biller, J and Vidal, R. CADASIL: A familial form of cerebrovascular disease leading to dementia Identification of two new families and a novel mutation. Neurology, 60:A368-A369, 2003. (Abstract)
138. Byrne, NP, Ito, M, Takao, M, Miravalle, L, Murrell, JR, Ghetti, B and Powers, JM. A novel form of senile dementia neuropathologically characterized by frontotemporal degeneration and leukoencephalopathy associated with a severe tau deposition predominantly in glia. J Neuropathol Exper Neurol, 61:460, 2002. (Abstract)
139. Cochran, EJ, Murrell, JR, Fox, J, Ringman, J and B, G. A novel mutation in the presenilin 1 (PS1) gene (A431E) associated with early-onset Alzheimer disease. J Neuropathol Exper Neurol, 60:544, 2001. (Abstract)
140. Davis RL, Shrimpton AE, Carrell RW, Lomas DA, Gerhard L, Baumann B, Lawrence DA, Yepes M, Kim TS, Ghetti B, Piccardo P, Takao M, Lacbawan F, Muenke M, Sifers RN, Bradshaw CB, Kent PF, Collins GH, Larocca D, Holohan PD. Association between conformational mutations in neuroserpin and onset and severity of dementia. Lancet, 359:2242-2247, 2002.
141. Delisle, MB, Uro-Coste, E, Rascol, O, Sinani, V, Piccardo, P, Takao, M, Vidal, R and B, G. A neurodegenerative disease with intranuclear deposits: clinical and neuropathologic studies. J Neuropathol Exper Neurol, 60:514, 2001. (Abstract)
142. Farlow MR, Murrell JR, Unverzagt FW, Phillips M, Takao M, Hulette C, Ghetti B. Familial Alzheimer’s Disease with Spastic Paraparesis Associated with a Mutation at Codon 261 of the Presenilin 1 Gene Therapeutics. In: Iqbal K, Sisodia SS, Winblad B, eds Alzheimer’s Disease: Advances in Etiology, Pathogenesis and Therapeutics Chichester: John Wiley and Sons Ltd, 53-60, 2001.
143. Ghetti, B, Piccardo, P, Parisi, J, Takao, M, Dlouhy, S, Cochran, EJ and Jh, F. Gerstmann-Straussler-Scheinker (GSS) disease with neurofibrillary tangles and PrP-amyloid plaques: a new family. J Neuropathol Exper Neurol, 60:537, 2001. (Abstract)
144. Hattab, EM, Murrell, JR, Yamaguchi, K, Unverzagt, FW, Foroud, T, Miravalle, L, Takao M, HC, Vidal, R, Farlow, MR and Ghetti, B. Widespread Abeta angiopathy, cotton wool plaques and pyramidal tract degeneration are the main neuropathologic features associated with the V261F mutation in the Presenilin 1 gene. J Neuropathol Exper Neurol, 62, 2003. (Abstract)
145. Miravalle, L, Murrell, JR, Takao, M, Glazier, B, Piccardo, P, Vidal, R and Ghetti, B. Genetic mutations associated with presenile dementia. Neurobiol Aging, 23:S322, 2002. (Abstract)
146. Miravalle, L, Murrell, JR, Takao, M, Richardson, R, Bassett, SS, Crain, B and B, G. Hippocampal pathology in patients with FTDP-17 and a mutation in the intron following exon 10 (+16) of the tau gene. J Neuropathol Exper Neurol, 60:548, 2001. (Abstract)
147. Murrell JR, Faber K, Alonso ME, Rasmussen A, Varpetian A, Macias MA, Cochran E, Gambetti P, Castellani RJ, Bauserman SC, Foroud T, Vidal R, Miravalle L, Ghetti B, Ringman JM. The A431E Presenilin 1 gene mutation associated with familial Alzheimer disease in individuals of Mexican descent: evidence for a founder effect. J Neuropathol Exper Neurol, 62, 2003. (Abstract)
148. Murrell, JF, Miravalle, L, Foster, NL, Albin, R, Takao, M and Ghetti, B. Early-onset familial Alzheimer disease (AD) from the first American report: a presenilin 1 (PS1) mutation found in descendants. J Neuropathol Exper Neurol, 60:543, 2001. (Abstract)
149. Piccardo, P, William, A, Dlouhy, SR, Farlow, MR, Takao, M and Ghetti, B. Two nonglycosylated prion protein (PrP) isoforms coexist within the same microregions in the brain of some individuals with sporadic Creutzfeldt-Jakob disease (sCJD). Exper Neurol, 60:549, 2001. (Abstract)
150. Powers, JM, Byrne, NP, Ito, M, Takao, M, Yankopoulou, D, Spillantini, MG and Ghetti, B. A novel leukoencephalopathy associated with tau deposits primarily in white matter glia. Acta Neuropathol, 106:181-187, 2003.
151. Rascol, O, Goizet, C, Labauge, P, Delisle, MB, Vidal, R, Calvas, P and Ghetti, B. A novel autosomic dominant movement disorder with intranuclear ferritin containing inclusions. Neurology, 60, 2003. (Abstract)
152. Ringman, JM, Jain, V, Murrell, J, Ghetti, B and Cochran, EJ. Human Gene Mutations: Gene Symbol: PSEN1. Hum Genetics, 109:242, 2001. (Abstract)
153. Takao M, Piccardo P, Murrell J, Miravalle L, Vidal R, Brashear A, Foster N, Towfighi J, Farlow M, Unverzagt F, Koto A, Hulette C, Conneally PM, Foroud T, Cochran E, Glazier B. Neuropathologic heterogeneity associated with Presenilin 1 gene mutations. Neurobiol Aging, 23:S417, 2002. (Abstract)
154. Takao, M, Ghetti, B, Hayakawa, I, Ikeda, E, Fukuuchi, Y, Miravalle, L, Piccardo, P, Murrell, JR, Glazier, BS and Koto, A. A novel mutation (G217D) in the Presenilin 1 gene (PSEN1) in a Japanese family: presenile dementia and parkinsonism are associated with cotton wool plaques in the cortex and striatum. Acta Neuropathol, 104:155-170, 2002.
155. Takao, M, Ghetti, B, Murrell, JR, Unverzagt, FW, Giaccone, G, Tagliavini, F, Bugiani, O, Piccardo, P, Hulette, CM, Crain, BJ, Farlow, MR and Heyman, A. Ectopic white matter neurons, a developmental abnormality that may be caused by the PSEN1 S169L mutation in a case of familial AD with myoclonus and seizures. J Neuropathol Exp Neurol, 60:1137-1152, 2001.
156. Takao, M, Ghetti, B, Yoshida, H, Piccardo, P, Narain, Y, Murrell, JR, Vidal, R, Glazier, BS, Jakes, R, Tsutsui, M, Spillantini, MG, Crowther, RA, Goedert, M and Koto, A. Early-onset dementia with Lewy bodies. Brain Pathol, 14:137-147, 2004.
157. Takao, M, Hayakawa, I, Ikeda, E, Koto, A, Fukuuchi, Y, Miravalle, L, Piccardo, P, Murrell, JR and Ghetti, B. A novel mutation (G217D) in the presenilin 1(PS1) gene associated with familial presenile dementia and Parkinsonism in a Japanese family. J Neuropathol Exp Neurol, 60:543, 2001. (Abstract)
158. Takao, M, Murrell, J, Piccardo, P, Unverzagt, FW, Farlow, MR, Vidal, R, Miravalle, L, Glazier, BS, Stuck, J, Foroud, T and Ghetti, B. Presenilin 1 mutation P264L associated with presenile dementia, cotton wool plaques and diffuse Lewy bodies. J Neuropathol Exp Neurol, 61:7, 2002. (Abstract)
159. Takao, M, Narain, Y, Spillantini, MG, Piccardo, P, Murrell, JR, Vidal, R, Crowther, RA, Goedert, M, Ghetti, B and Koto, A. Atypical form of diffuse Lewy body disease with onset at 13 years of age. J Neuropathol Exp Neurol, 61:459, 2002. (Abstract)
160. Vidal, R, Azzarelli, B, Miravalle, L, Olson, J, Nukes, T, Biller, J and Ghetti, B. CADASIL in two North American Caucasian families. J Neuropathol Exper Neurol, 62, 2003. (Abstract)
161. Vidal, R, Benson, MD, Liepnieks, JM, Yazaki, M, Miravalle, L, Uro-Coste, E, Delisle, MB and B, G. A neurodegenerative disease with intranuclear protein deposits: electron microscopic and biochemical studies. J Neuropathol Exper Neurol, 60:515, 2001. (Abstract)
162. Vidal, R, Delisle, MB and Ghetti, B. Neurodegeneration caused by proteins with an aberrant carboxyl-terminus. J Neuropathol Exp Neurol, 63:787-800, 2004.
163. Vidal, R, Delisle, MB, Liepnieks, JJ, Uro-Coste, E, Yazaki, M, Rascol, O, Siani, V, Miravalle, L, Takao, M, Piccardo, P, Calvas, P, Benson, MD and Ghetti, B. CNS and systemic deposition of ferritin and iron associated with a novel autosomal dominant neurodegenerative disease. J Neurosci, 573:14, 2001. (Abstract)
164. Vidal, R, Delisle, MB, Rascol, O and Ghetti, B. Hereditary ferritinopathy. J Neurol Sci, 207:110-111, 2003.
165. Vidal, R, Delisle, MB, Takao, M, Miravalle, L, Uro-Coste, E, Liepnieks, JJ, Yazaki M, SV, Piccardo, P, Calvas, P, Benson, MD, Rascol, O and B, G. Autosomal dominant neurodegenerative disease associated with accumulation of ferritin. J Neuropathol Exper Neurol, PG55, 2002. (Abstract)
166. Vidal, R, Delisle, MB, Takao, M, Miravalle, L, Uro-Coste, E, Liepnieks, JJ, Yazaki, M, Siani, V, Piccardo, P, Calvas, P, Murrell, J, Benson, MD, Rascol, O and B, G. A familial adult-onset autosomal dominant neurodegenerative disease associated with cytoplasmic and intranuclear accumulation of ferritin. Neurobiol Aging, 23:S205, 2002. (Abstract)
167. Vidal, R, Delisle, MB, Takao, M, Miravalle, L, Uro-Coste, E, Liepnieks, JJ, Yazaki, M, Siani, V, Piccardo, P, Calvas, P, Murrell, JR, Benson, MD, Rascol, O and Ghetti, B. A familial autosomal dominant disease associated with intracytoplasmic and intranuclear ferritin accumulation. Clin Neuropathol, 21:136-137, 2002. (Abstract)
168. Vidal, R, Delisle, MB, Takao, M, Uro-Coste, E, Calvas, P, Benson, MD, Miravalle, L, Rascol, O and Ghetti, B. Intracellular ferritin accumulation in neural and extraneural tissue characterizes a neurodegenerative disease associated with a TC insertion in exon 4 of the Ferritin Light Polypeptide (FTL) gene. Neurology, 62:A177, 2004. (Abstract)
169. Vidal, R, Ghetti, B, Takao, M, Brefel-Courbon, C, Uro-Coste, E, Glazier, BS, Siani, V, Benson, MD, Calvas, P, Miravalle, L, Rascol, O and Delisle, MB. Intracellular ferritin accumulation in neural and extraneural tissue characterizes a neurodegenerative disease associated with a mutation in the ferritin light polypeptide gene. J Neuropathol Exp Neurol, 63:363-380, 2004.
170. Vidal, R, Piccardo, P, Miravalle, L, Takao, M, Frangione, B and B, G. Senile dementia associated with Ab angiopathy and tau perivascular pathology but not neuritic plaques in patients homozygous for the APOE 4 allele. J Neuropathol Exper Neurol, PG54, 2002. (Abstract)
171. Yamaguchi, K, Miravalle, L, Piccardo, P, Murrell, JR, Foroud, T, Vidal, R, Unverzagt, FW, Farlow, MR and Ghetti, B. Phenotypic variability associated with the Presenilin 2 N141I mutation in individuals of Volga-German descent. J Neuropathol Exper Neurol, 62:543, 2003. (Abstract)

SAS Output

Principal Investigator: Chris Clark (NACC Project #Clark)

Title: Does the onset of AD differ in Latinos

Lead Institutions: Univ of Pennsylvania

172. Clark, CM, DeCarli, C, Mungas, D, Chui, H, Higdon, R, Nunez, J, Fernandez, H, Negron, M, Manly, J, Hernandez, I, Ferris, S, Perez, A, Torres, M, Ewbank, D, Glosser, G and van Belle, G. Latino patients with Alzheimer's disease have an earlier age of symptom onset compared to Anglos. Neurobiol Aging, 25:S106, 2004. (Abstract)
173. Clark, CM, DeCarli, C, Mungas, D, Chui, HI, Higdon, R, Nunez, J, Fernandez, H, Negron, M, Manly, J, Ferris, S, Perez, A, Torres, M, Ewbank, D, Glosser, G and van Belle, G. Earlier onset of Alzheimer disease symptoms in Latino individuals compared with Anglo individuals. Arch Neurol, 62:774-778, 2005.

SAS Output

Principal Investigator: Michael Hughes (NACC Project #Hughes)

Title: ADC Collaborative Networks

Lead Institutions: Univ of Pennsylvania

174. Hughes ME, Peeler J, Hogenesch JB, Trojanowski JQ. The Growth and Impact of Alzheimer Disease Centers as Measured by Social Network Analysis. JAMA Neurology, in press 2014, PMC Journal - In Process.

SAS Output

NACC-Funded Secondary Data Analyses: (TOTAL of 35)

SAS Output

Principal Investigator: Brittany Dugger, PhD (NACC Project #2013-JI-03)

Title: Relationship of Cardiovascular Risk Factors to Dementia Subtypes

Lead Institutions: Arizona ADC

1. Dugger BN, Hentz JG, Adler CH, Sabbagh MN, Shill HA, Jacobson S, Caviness JN, Belden C, Driver-Dunckley E, Davis KJ, Sue LI, Beach TG, Consortium atAPD. Neuropathological Outcome of Prospectively Followed Normal Elderly Brain Bank Volunteers. Alzheimers and Dementia, 9:P336, 2013. (Abstract)
2. Dugger BN, Malek-Ahmadi M, Monsell S, Kukull W, Woodruff B, Reiman E, Beach TG, Wilson J. Cardiovascular Risk Factors and Their Interactions Among Clinically Defined Neurodegenerative Diseases. AAIC 2014, submitted 2014. (Abstract)

SAS Output

Principal Investigator: Maritza Dowling MS, PhD (NACC Project #2012-JI-04)

Title: Missing Data and the Identification of Optimal Predictors of Conversion to AD

Lead Institutions: University of Wisconsin

3. Dowling, N.M.. Missing Data and the Identification of Optimal Predictors of Conversion to AD. Alzheimers and Dementia, 9:P776-777, 2013. (Abstract)

SAS Output

Principal Investigator: Joshua Grill (NACC Project #2012-JI-09)

Title: Assessing Disease Progression Among Alzheimer's Disease Patients With Adult Child Study Partners

Lead Institutions: University of California, Los Angeles

4. Grill JD, Zhou Y, Karlawish J, Elashoff D. Does study partner type impact the rate of Alzheimer’s disease progression. J Nutr Health Aging, 17:816, 2013. (Abstract)
5. Grill JD, Zhou Y, Karlawish J, Elashoff D. Does study partner type impact the rate of Alzheimer’s disease progression?. J Alzheimers Dis, 38:507-514, 2014, PMC3842422.

SAS Output

Principal Investigator: Katherine Gifford PhD (NACC Project #2011-JI-08)

Title: Subjective Memory Complaint and Cognitive Aging

Lead Institutions: Boston University

6. Gifford KA, Liu D, Lu Z, Carmona H, Romano R, Tripodis Y, Martin B, Kowall N, Jefferson AL. Inclusion of an informant yields strong associations between cognitive complaint and longitudinal cognitive outcomes in non-demented elders. J Alzheimers Dis, in press 2014, PMC in process.
7. Gifford KA, Liu D, Lu Z, Tripodis Y, Cantwell N, Palmisano J, Kowall N, Jefferson AL. The source of cognitive complaints differentially predicts diagnostic conversion in non-demented older adults. Alzheimers and Dementia, in press 2013, NIHMS484343.
8. Gifford, KA, Carmona, H, Tripodis, Y, Martin, B, Cantwell, N, Kowall, N, Jefferson, AL. Subjective Cognitive Complaint Predicts Cognitive and Functional Trajectory in Individuals with Mild Cognitive Impairment. Int'l Neuropsychological Society Meeting, 2012. (Abstract)
9. Tripodis, Y, Palmisano, J, Gentile, A, Jefferson, A. Subjective Complaint and Cognitive Aging. Alzheimer's and Dementia, 7:S545, 2011. (Abstract)

SAS Output

Principal Investigator: Patrick Brown PhD (NACC Project #2010-JI-01)

Title: Common Functional Deficits in MCI and Dementia

Lead Institutions: Columbia University

10. Brown PJ, Liu X, Sneed JR, Pimontel MA, Devanand DP, Roose SP. Speed of processing and depression affect function in older adults with mild cognitive impairment. Am J Geriatric Psychiatry, 21:675-684, 2013, PMC3410965.
11. Brown PJ, Sneed JR, Rutherford B, Devanand DP, Roose SP. The Nuances of Cognition and Depression in Older Adults: The Need for a Comprehensive Assessment. Intl J Geriatric Psychiatry, in press 2013, NIHMS525662.

SAS Output

Principal Investigator: Berneet Kaur, MD (NACC Project #2010-JI-05)

Title: The Influence of Smoking History on the Phenotype and Pathology of Dementia

Lead Institutions: University of California, Davis

12. Kaur B, Harvey D, Tong E, Hofstetter CR, DeCarli C, Olichney J. A Comparison of Extrapyramidal Signs Between Smokers and Nonsmokers with Dementia. Neurology, 80:P07.153, 2013. (Abstract)
13. Kaur B, Harvey D, Tong E, Hofstetter CR, DeCarli C, Olichney J. The relationship of smoking history and vascular risk factors to motor parkinsonism in dementia. Neurology, 78(1):P04202, 2012. (Abstract)

SAS Output

Principal Investigator: Kathleen Hayden PhD (NACC Project #2008-JI-02)

Title: Identification of Cognitive Endophenotypes

Lead Institutions: Duke University

14. Hayden KM, Kuchibhatla M, Plassman BL, Burke JR, Romero HR, Welsh-Bohmer KA. Pre-clinical cognitive phenotypes for Alzheimer’s disease: a latent profile approach. Am J Geriatr Psychiatry, in press 2013, NIHMS529843.
15. Hayden KM, Kuchibhatla M, Plassman BL, Romero HR, Burke JR, Welsh-Bohmer KA. Pre-clinical cognitive phenotypes for Alzheimer’s disease: a latent profile approach. Alzheimers and Dementia, 8:P363, 2012. (Abstract)
16. Hayden, KM, Jones, RN, Zimmer, C, Plassman, B, Browndyke, JN, Pieper, C, Warren, LH and Welsh-Bohmer, KA. Factor Structure of the National Alzheimer's Coordinating Centers Uniform Dataset Neuropsychological Battery: An evaluation of invariance between and within groups over time. Alzheimer Dis Assoc Disord, 25:128-137, 2011, PMC3101374.
17. Hayden, KM, Warren, LH, Plassman, B, Browndyke, J, Pieper, C, Sanders, L and Welsh-Bohmer, KA. Neuropsychological Domains in Mild Cognitive Impairment and Normal Aging: Results from the NACC UDS Study. Alzheimer's and Dementia, 5:P448, 2009. (Abstract)

SAS Output

Principal Investigator: Ann Mayo, RN DNSc (NACC Project #2007-JI-01)

Title: Determinants of Judgment and Problem Solving Among Patients with Dementia

Lead Institutions: UC, San Francisco

18. Mayo AM, Wallhagen M, Cooper BA, Mehta K, Ross L, Miller B. The relationship between functional status and judgment/problem solving among individuals with dementia. Int J Geriatr Psychiatry, 28:514-521, 2013, PMC3496819.
19. Mayo, AM, Wallhagen, M, Cooper, BA, Mehta, K, Ross, L and Miller, B. Determinants of Judgment and Problem Solving in Persons with Dementia. American Geriatrics Society Annual Meeting in Chicago on April 30, 2009, 2009. (Abstract)

SAS Output

Principal Investigator: Liana Apostolova, MD (NACC Project #2007-JI-02)

Title: Behavioral Reserve in MCI and AD

Lead Institutions: University of California, Los Angeles

20. Apostolova LG, Di LJ, Elashoff D, Tseng CH, Fairbanks L, Cummings JL. Risk factors for behavioral abnormalities in mild cognitive impairment and mild Alzheimer’s disease. Dement Geriatr Cogn Disord, 37:315-326, in press 2014, NIHMS561447.
21. Apostolova LG, Di LJ, Tseng CH, Fairbanks L, Elashoff D, Cummings JL. Behavioral reserve in mild cognitive impairment and mild Alzheimer’s disease. Alzheimers and Dementia, 8:P323, 2012. (Abstract)
22. Apostolova LG, Di LJ, Tseng CH, Fairbanks L, Elashoff D, Cummings JL. Comparison of the prevalence of neuropsychiatric behaviors between amnestic and nonamnestic MCI subjects. Alzheimers and Dementia, 8:P135, 2012. (Abstract)
23. Apostolova, L, Tseng, C, Fairbanks, L, Elashoff, D and Cummings, J. Effect of age, gender, marital status and education on behavioral symptoms in MCI and mild AD subjects. Neurology, 74:A21, 2010. (Abstract)

SAS Output

Principal Investigator: Catherine Roe (NACC Project #2005-JI-03)

Title: Education, the cognitive reserve hypothesis, and Alzheimer’s Disease Without Dementia

Lead Institutions: Washington University

24. Roe, CM, Xiong, C, Grant, E, Miller, JP and Morris, JC. Education and reported onset of symptoms among individuals with Alzheimer disease. Arch Neurol, 65:108-111, 2008, PMC2830808.
25. Roe, CM, Xiong, C, Miller, JP and Morris, JC. Diffuse and Neuritic Plaques, Neurofibrillary Tangles, and APOE Genotype in Preclinical AD. Alzheimer's and Dementia, 2:S247, 2006. (Abstract)
26. Roe, CM, Xiong, C, Miller, JP and Morris, JC. Education and Alzheimer disease without dementia: support for the cognitive reserve hypothesis. Neurology, 68:223-228, 2007.
27. Roe, CM, Xiong, C, Miller, JP, Cairns, NJ and Morris, JC. Interaction of neuritic plaques and education predicts dementia. Alzheimer Dis Assoc Disord, 22:188-193, 2008, PMC2770714.
28. Roe, CM, Xiong, C, Miller, P and Morris, JC. Education and Preclinical Alzheimer's Disease without Dementia. Alzheimer’s and Dementia, 2:S146, 2006. (Abstract)
29. Roe, CM, Xiong, CJ, Miller, JP and Morris, J. Education and Neuropathological Alzheimer s Disease, With and Without Dementia. Neurology, 66:A218, 2006. (Abstract)

SAS Output

Principal Investigator: Michael Rapp A. (NACC Project #2005-JI-09)

Title: Neuropathological Changes in Dementia in Patients with Co-morbid Depression

Lead Institutions: Mount Sinai School of Medicine

30. Rapp, MA, Haroutunina, V and Sano, M. Increased Plaques and Tangles in Alzheimer's Disease Patients with Co-morbid Depression. Society for Biological Psychiatry Annual Meeting, Toronto, Canada, 2006. (Abstract)
31. Rapp, MA, Schnaider-Beeri, M, Purohit, DP, Perl, DP, Haroutunian, V and Sano, M. Increased neurofibrillary tangles in patients with Alzheimer disease with comorbid depression. Am J Geriatr Psychiatry, 16:168-174, 2008.

SAS Output

Principal Investigator: Kala Mehta (NACC Project #2005-JI-11)

Title: Ethnic Differences in Alzheimer’s Disease Survival and Pathology

Lead Institutions: University of California, San Francisco

32. Mehta, K, Kurland, B, Barnes, D, Yaffe, K, Miller, B and Perez-Stable, EJ. African American and Latino AD Patients have longer survival than white AD patients: data from the National Alzheimer's Coordinating Center datasets. National Meeting of the Resource Center for Minority Aging Research, 2006. (Abstract)
33. Mehta, KM, Kurland, B, Barnes, D, Yaffe, K, Perez-Stable, E and Miller, B. African American and Latino Alzheimer's disease patient's have longer survival than white Alzheimer's disease patients: Data from the National Alzheimer's Coordinating Center datasets. Neurology, 66:A218, 2006. (Abstract)
34. Mehta, KM, Yaffe, K, Perez-Stable, EJ, Stewart, A, Barnes, D, Kurland, BF and Miller, BL. Race/ethnic differences in AD survival in US Alzheimer's Disease Centers. Neurology, 70:1163-1170, 2008, PMC2830859.
35. Ontaneda D, Mehta KM, Perez-Stable E. Race/ethnic differences in AD survival in us Alzheimer's disease centers. Neurology, 72:1620, 2009, PMC Journal - In Process.

NACC - ADC Collaboration in External Studies (RFA-AG-03-005 and RFA-AG-05-006) (by project): (TOTAL of 72)

SAS Output

PI: Carl Cotman, PhD

Lead Institutions: University of California, Irvine

Title: Brain Aging and Gene Expression Patterns Using Microarrays

Agency: NIA - RO1 AG023173

Date Funded: 9/1/2003

1. Berchtold, NC, Cribbs, DH, Coleman, PD, Rogers, J, Head, E, Kim, R, Beach, T, Miller, C, Troncoso, J, Trojanowski, JQ, Zielke, HR and Cotman, CW. Gene expression changes in the course of normal brain aging are sexually dimorphic. Proc Natl Acad Sci U S A, 105:15605-15610, 2008, PMC2563070.
2. Pan, F, Chiu, CH, Pulapura, S, Mehan, MR, Nunez-Iglesias, J, Zhang, K, Kamath, K, Waterman, MS, Finch, CE and Zhou, XJ. Gene Aging Nexus: a web database and data mining platform for microarray data on aging. Nucleic Acids Res, 35:D756-759, 2007, PMC1669755.
3. Parachikova, A, Agadjanyan, MG, Cribbs, DH, Blurton-Jones, M, Perreau, V, Rogers, J, Beach, TG and Cotman, CW. Inflammatory changes parallel the early stages of Alzheimer disease. Neurobiol Aging, 28:1821-2833, 2007, PMC2198930.

SAS Output

PI: Douglas Galasko, MD

Lead Institutions: University of California, San Diego

Title: Biomarkers in Aging, MCI and Alzheimer’s Disease

Agency: NIA - RO1 AG023185

Date Funded: 9/1/2003

4. Portelius, E, Bogdanovic, N, Gustavsson, MK, Volkmann, I, Brinkmalm, G, Zetterberg, H, Winblad, B and Blennow, K. Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer's disease. Acta Neuropathol, 120:185-193, 2010, PMC3568930.
5. Li, G, Peskind, ER, Millard, SP, Chi, P, Sokal, I, Yu, CE, Bekris, LM, Raskind, MA, Galasko, DR and Montine, TJ. Cerebrospinal fluid concentration of brain-derived neurotrophic factor and cognitive function in non-demented subjects. PLoS ONE, 4:e5424, 2009, PMC2671606.
6. Petrie EC, Cross DJ, Galasko D, Schellenberg GD, Raskind MA, Peskind ER, Minoshima S. Preclinical evidence of Alzheimer changes: convergent cerebrospinal fluid biomarker and fluorodeoxyglucose positron emission tomography findings. Arch Neurol, 66:632-637, 2009, PMC2718788.
7. Peskind, ER, Li, G, Shofer, J, Quinn, JF, Kaye, JA, Clark, CM, Farlow, MR, DeCarli, C, Raskind, MA, Schellenberg, GD, Lee, VM and Galasko, DR. Age and apolipoprotein E*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition. Arch Neurol, 63:936-939, 2006.
8. Peskind, ER, Riekse, R, Quinn, JF, Kaye, J, Clark, CM, Farlow, MR, Decarli, C, Chabal, C, Vavrek, D, Raskind, MA and Galasko, D. Safety and acceptability of the research lumbar puncture. Alzheimer Dis Assoc Disord, 19:220-225, 2005.

SAS Output